Document:

Exhibit 10.38

 

Certain identified information
has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly
disclosed. [***] indicates that information has been redacted.

 

 

 

 

12.13.2016

 

 

 

 

 

 

TECHNOLOGY PURCHASE AGREEMENT

 

 

 

 

 

 

regarding

 

acquisition of the Gyronimo Platform

 

 

 

 

 

 

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

TABLE OF CONTENTS

 

 

	 	CLAUSE	PAGE
	 	 	 	 
	 	I	GENERAL PROVISIONS	4
	 	1.	Current Status	4
	 	2.	Purchased Assets	4
	 	3.	Execution Date	6
	 	4.	Suspensive Conditions	6
	 	5.	Purchase Price	7
	 	6.	Milestones	8
	 	7.	Earn-Out	9
	 	8.	Commercialization	12
	 		 	 
	 	II.	TRANSFER OF THE ASSETS	13
	 	9.	Transfer of the Assets	13
	 	10.	Employees	15
	 	11.	Conduct up to the Execution Date	16
	 	12	Technology Transfer	16
	 	 	 	 
	 	III.	GRANT-BACK	18
	 	13.	Carve-Out	18
	 	 	 	 
	 	IV.	THE SELLERS’ LIABILITY	19
	 	14.	The Sellers’ Warranty	19
	 	15.	Limitation of Liability	21
	 	16.	Third-Party Claims Procedure	23
	 	17.	Indemnifications	24
	 	 	 	 
	 	V.	ADDITIONAL PROVISIONS	25
	 	18.	Non-Competition and Non-Solicitation	25
	 	19.	Confidentiality and Publications	26
	 	20.	Compliance	28
	 	21.	Disclosures and Declarations	28
	 	22.	Costs	30
	 	23.	Final Provisions	30

 

 

 

 

 

 

    	2 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

THIS TECHNOLOGY PURCHASE
AGREEMENT (the “Agreement” or “this
Agreement”) was entered into on 12/13/2016

BETWEEN:

 

 

		(1)	Systec Elektronik und Software GmbH, Nottulner Landweg 90,
48161 Münster

- hereinafter, “Systec”
-

		(2)	Carpegen GmbH, Mendelstra8e 11, 48149 Münster

 

 

- hereinafter “Carpegen”
-

and

		(3)	Curetis
GmbH, Max-Eyth-Straße 42, 71088 Holzgerlingen

 

- hereinafter the “Purchaser”
or “Curetis” -

Parties
(1) and (2) shall also hereinafter be referred to collectively as the “Sellers” and separately as a “Seller.”
Parties (1) to (3) shall hereinafter be referred to collectively as the “Parties” and separately as a “Party.”

 

PRELIMINARY REMARKS

 

		(A)	The Sellers have jointly developed a technology platform for a
proprietary microbiological point-of-care diagnostic system to analyze nucleic acids. The Sellers intend to sell this diagnostic
system, including the assets, technology, and know-how related to it and specified in this Agreement (hereinafter referred to collectively
as the “Gyronimo Platform”) to the Purchaser or, to the extent that know-how is not exclusively related to the
Gyronimo Platform, to license it to the Purchaser. The Parties have a mutual fundamental understanding that no employment agreements
are allocated to the Gyronimo Platform that could be transferred to the Purchaser. A transfer of employment agreements to the Purchaser
is therefore not intended.

		(B)	The Purchaser develops, produces, and markets products and solutions
to fight infectious diseases and is interested in acquiring the Gyronimo Platform.

		(C)	The Purchaser intends to develop the Gyronimo Platform to the production
stage and put it into serial production.

 

    	3 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

To this end, the Parties enter into the following

 

TECHNOLOGY PURCHASE AGREEMENT

 I.   GENERAL PROVISIONS

		1.	CURRENT STATUS

		1.1	Systec is entered into the Commercial Registry
of the Münster Local Court under HRB 4737. A current excerpt from the Systec entry in the Commercial Registry and the list
of its current shareholders are attached to this Agreement as Annex 1.1.

		1.2	Carpegen is entered into the Commercial
Registry of the Münster Local Court under HRB 6177. A current excerpt from the Carpegen entry in the Commercial Registry and
the list of its current shareholders are attached to this Agreement as Annex 1.2.

		1.3	The Purchaser is entered into the Commercial
Registry of the Stuttgart Local Court under HRB 756134. A current excerpt from its entry in the Commercial Registry is attached
to this Agreement as Annex 1.3.

 

		2.	PURCHASED ASSETS

		2.1	The purchased assets are all the Gyronimo
Platform assets detailed in this Agreement and defined in Clauses 2.2 to 2.5 below (hereinafter referred to collectively as the
“Purchased Assets”).

2.2        
The specific Purchased Assets include:

		2.2.1	The following fixed and current assets:

		(a)	the CAD 3D models and device and analyzer
technical drawings listed in Annex 2.2.1(a);

		(b)	the prototypes, prototype parts, test stands,
and test equipment listed in Annex 2.2.1(b);

		(e)	the CAD 30 models and the technical drawings of application cartridges listed
in Annex 2.2.1(c);

(d)       the
production tools listed in Annex 2.2.1(d);

 

    	4 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		2.2.2	The following Gyronimo Platform intangible
assets that have not been included on the balance sheet:

		(a)	the patents and patent applications listed in Annex 2.2.2(a);

		(b)	the brands listed in Annex 2.2.2(b);

(e)       the
software listed in Annex 2.2.2(c);

		2.2.3	To the extent that they are not expressly
specified in the annexes listed in Clauses 2.2.1 to 2.2.2, the business documents the Sellers have available and possess on the
day this Agreement is signed and/or on the Execution Date, and which are exclusively related to the Gyronimo Platform, but do not
fall under Clause 2.4, as well as the know-how specified and embodied in Annex 2.2.3 (these business documents and
this know-how shall hereinafter be collectively referred to as the “Gyronimo Know-How”).

The
assets specified in Clauses 2.2.1, 2.2.2, and 2.2.3, the intangible assets, and the know-how shall hereinafter be referred to collectively
as the “Acquired Assets.”

If
and to the extent that the Sellers must retain documents due to retention and documentation obligations, the Sellers who cite such
obligations are each (only) obligated to give the Purchaser copies of the documents in question.

		2.3	To be clear: The Purchased Assets also
include the services to be provided in connection with the technology transfer pursuant to Clause 12.

		2.4	As regards the know-how the Sellers use
in connection with the Gyronimo Platform, but not exclusively in that connection, the Sellers hereby grant the Purchaser, in connection
with the transfer of the entire Gyronimo Platform, a worldwide, irrevocable, sub-licensable license, which shall be included in
the purchase price, but which shall be otherwise free-of-charge, as follows:

		2.4.1	To the extent the know-how specified in Annex
2.4 is affected – know-how the Sellers possess on the day this Agreement is signed and/or on the Execution Date,
and which is used in connection with the Gyronimo Platform, but also for other projects the Sellers have – the license shall
be granted on an exclusive basis limited to use for business or development activities in connection with the Gyronimo and/or Unyvero
Platform.

 

    	5 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		2.4.2	To the extent that other general know-how
of the Sellers is affected – which can be reasonably considered to be economically and technologically required for the operation
and exploitation of the Gyronimo Platform in the form in which it exists on the Execution Date – the license shall be granted
on a non-exclusive basis limited to use for business or development activities in connection with the Gyronimo Platform.

		2.5	The Purchased Assets shall also include
the obligations specified in Annex 2.5, which derive from BMBF [German Federal Ministry of Education and Research]
approval decisions for the POCDENTAL and MOBIDOC projects. The Purchaser shall assume these obligations for itself and its legal
successors. Annex 2.5 also indicates the extent to which the obligations specified in it have already been fulfilled.

 

		3.	EXECUTION DATE

		3.1	The Sellers hereby sells the Purchased Assets
to the Purchaser with effect in personam and in rem with effect as of the Execution Date (as defined below).

		3.2	The Purchased Assets shall be transferred,
in accordance with the provisions of Section II of this Agreement, on the Execution Date, with the arrangements Section II governs
being subject to realization of the Suspensive Conditions specified in Clause 4. If the Parties do not amicably agree to another
date, the Execution Date shall be the last calendar day of the month in which this Agreement is signed (hereinafter, the “Execution
Date"). If the Execution Date falls on a week day that is not a Banking Day as defined by this Agreement (i.e., a week
day on which the banks in Frankfurt am Main are open for normal business, hereinafter a “Banking Day”), the
Execution Day shall be the following Banking Day.

 

		4.	SUSPENSIVE CONDITIONS

		4.1	On the Execution Date, the following Suspensive
Condition (hereinafter, the “Suspensive Condition”) must either have been realized or its need to be realized
must have been waived: payment of the provisional Purchase Price in accordance with Clause 5.

 

 

    	6 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

The Parties shall
inform one another immediately when the Suspensive Condition has been realized.

		4.2	Each of the Sellers shall have the right
to withdraw from this Agreement if the Suspensive Condition in Clause 4.1 is not realized within two months of the signing of this
Agreement and if its needing to be realized has not been waived by that deadline.

		4.3	Withdrawal from this Agreement shall be
expressed in writing. The Sellers must give notice of withdrawal jointly. If a withdrawal is valid, all obligations among the Parties
shall lapse with the exception of the obligations of confidentiality (Clause 19) and responsibility for costs (Clause 22).

 

		5.	PURCHASE PRICE

		5.1	Subject to the Additional Purchase Price
pursuant to Clauses 5.1.1 and 5.1.2, as well as to the Earn-Out pursuant to Clause 7, the Purchase Price for the Purchased Assets
shall be EUR 5,000,000.00 (in words: five million euro) net, plus the legal value-added tax (hereinafter, the “Provisional
Purchase Price”). If the Milestones defined in Clauses 6.1 and/or 6.2 are reached, the Purchase Price shall increase
as follows:

		5.1.1	If Milestone I is reached, the Purchase
Price shall increase one time by EUR 1,000,000.00 (in words: one million euro) net, plus the legal value-added tax (hereinafter,
the “Additional Purchase Price Milestone I”).

		5.1.2	If Milestone II is reached, the Purchase
Price shall increase one time by EUR 1,500,000.00 (in words: one million five hundred thousand euro) net, plus the legal value-added
tax (hereinafter, the “Additional Purchase Price Milestone II” and, together with the Provisional Purchase Price
and the Additional Purchase Price Milestone I, the “Purchase Price”).

		5.2	The Purchase Price and the Earn-Out shall
be distributed between the Sellers [each shall get half] (hereinafter, the “Purchase Price Distribution Ratio”).

		5.3	The Purchase Price shall become due and payable as follows:

		5.3.1	the Provisional Purchase Price, on the Execution Date;

		5.3.2	the amount of the Additional Purchase Price
Milestone I within 20 Banking Days if and as soon as Milestone I is realized pursuant to Clause 6.1; and

		5.3.3	the amount of the Additional Purchase Price
Milestone II within 20 Banking Days if and as soon as Milestone II is realized pursuant to Clause 6.2.

 

    	7 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

The
Sellers shall have no right to interest on the Additional Purchase Price Milestone I or the Additional Purchase Price Milestone
II.

		5.4	Payments of the Purchase Price shall be
made in accordance with the Purchase Price Distribution Ratio to the following Seller bank accounts:

Account
holder: [***]

Bank:
[***]

IBAN: [***]

BIC: [***]

 

Account holder: [***]

Bank: [***]

IBAN: [***]

BIC: [***]

In
order for payment to be made on time pursuant to this Clause, the funds must be credited to the accounts of the respective Sellers
by the deadline.

		5.5	The Sellers shall be obligated, upon request,
to provide the Purchaser with an invoice that lists the value-added tax separately for the portions of the Purchase Price subject
to value-added tax pursuant to § 14 UStG [German Value-Added Tax Act].

 

		6.	MILESTONES

		6.1	Milestone I

As
regards the possibility of increasing the Purchase Price pursuant to Clause 5.1.1, the Parties agree to the following milestone
(hereinafter, “Milestone I”):

Fulfilment
of the prerequisites and first-time CE/IVD designation for the Gyronimo Platform and its first Application Cartridge, via issuance
of a conformity declaration or, if required, via a Certification Body.

		6.2	Milestone II

As
regards the possibility of increasing the Purchase Price pursuant to Clause 5.1.2, the Parties agree to the following Milestone
(hereinafter, “Milestone II” and, together with Milestone I, the “Milestones”):

First-time
approval of the Gyronimo Platform and its first Application Cartridge by the United States Food and Drug Administration (FDA).

 

 

    	8 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		6.3	The above Clauses 6.1 and 6.2 apply analogously
in the case where the Milestones are not achieved by the Purchaser but rather by a third party to whom the Gyronimo Platform has
been licensed or sold.

		6.4	The Purchase is obligated to inform the
Sellers in writing immediately, and without having been requested to do so by the Sellers, of achievement of the respective Milestones.

		6.5	“Application Cartridges”
as defined by this Agreement shall be all cartridges that are essentially based on the Gyronimo Platform technology, including
all plastic parts and reagents, that detect analytes in test sample materials via a biochemical or molecular-biological reaction.

		6.6	“Analyzers” as defined
by this Agreement shall be all modules and devices that are essentially based on the Gyronimo Platform technology and are required
to process Application Cartridges.

 

		7.	EARN-OUT

 

		7.1	When the Purchaser commercializes
the Gyronimo Platform by selling Application Cartridges for it to third parties, the Sellers shall receive a licensing fee of [***]%
of the net sales revenue from the Gyronimo Platform Application Cartridges marketed
and commercialized by the Purchaser, up to a total maximum of EUR 9,000,000.00 (in words: nine million euro) net, plus the legal
value-added tax (hereinafter, the “Application Cartridges Earn-Out”).

		7.2	If commercial use is
made of the Analyzers separately from the Application Cartridges, e.g. instead of using the Application Cartridges commercially
or to an extent comparable with commercial use of the Application Cartridges, the Sellers shall receive a Lump-Sum Amount (“Lump-Sum
Amount”) of EUR [***] up to a maximum total amount of EUR 9,000,000.00
(in words: nine million euro) net, plus the legal value-added tax (hereinafter, the “Analyzers Earn-Out”; the
Application Cartridges Earn-Out and the Analyzers Earn-Out shall hereinafter be referred to collectively as the “Earn-Out”).
The Lump-Sum Amount shall be based on the receipt of a coverage amount (“Gross Profit”) per Analyzer of ca.
EUR [***], and application of a licensing fee of [***]%
to this Gross Profit. Should the actual Gross Profit be significantly higher or lower than this estimate, the Parties shall, at
the end of the fiscal year in question, reach an amical agreement in good faith on another Lump-Sum Amount per Analyzer.

 

    	9 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

The
Purchaser shall be obligated to inform the Sellers of any possible change in the use of the Analyzers within one month of the end
of each fiscal year. The Sellers shall assert any objections to the Lump-Sum Amount in writing within one month of receipt of such
notice. If, within two (2) months of the Seller receiving notice of the objections, the Parties have not reached agreement on a
new Lump-Sum Amount, a new Lump-Sum Amount shall, at the request of both Parties, be bindingly determined by an expert arbitrator
appointed by the IHK [German Chamber of Industry and Commerce] on the basis of the economic grounds used to determine the original
Lump-Sum Amount. The expert shall set the costs of his/her mandate in accordance with §§ 91 ff. ZPO [German Code of Civil
Procedure].

		7.3	The maximum Earn-Out shall be a total of
EUR 9,000,000.00 (in words: nine million euro) net, plus the legal value-added tax; there shall be no right to payment of an Earn-Out
beyond this amount.

		7.4	If, so that the Purchaser
or any of its contractual partners may use the Gyronimo Platform, the Purchaser or its contractual partners should be required
to acquire licenses from third parties due to impending violation of the third-party property rights specified in Annex 7.4,
which the Purchaser has identified or may still identify in the future, during due diligence freedom-to-operate research, as possibly
conflicting, the Purchaser may deduct the licensing fees to be paid to these third parties from the Earn-Out to be paid to the
Sellers, although the Sellers shall always receive, as Earn-Out, minimum licensing fees of [***]%
of the net sales revenue pursuant to Clause 7.6. Any licenses required for assay technology (e.g., qPCR, primers, probes, dyes,
and quenchers), assay content (e.g., biomarkers), and background operating system licenses (e.g., Windows), shall be explicitly
excluded from this stack-cap regulation. This shall only apply, however, if the third-party property rights conflict with the Gyronimo
Platform at its stage of development as of the Execution Date.

		7.5	Clauses 6 and 7.1 shall correspondingly
apply if the Purchaser does not itself sell the Application Cartridges or Analyzers for the Gyronimo Platform but rather licenses
them to a third party or allows third parties to sell them, or if it commercializes the Gyronimo Platform, in its current or in
a further-developed form, in another manner (e.g., sale or licensing of the Gyronimo Platform to a third party). In this case,
the Sellers shall be compensated as if the Purchaser had achieved the Milestones or as if the third parties’ net sales revenues
were those of the Purchaser.

 

    	10 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		7.6	If the Purchaser itself sells the Gyronimo
Platform Application Cartridges, “Net Sales Revenue” as defined in this Agreement shall mean the gross amounts
invoiced for Gyronimo Platform Application Cartridges sold by the Purchaser, minus the following items:

		7.6.1	shipping costs;

		7.6.2	purchase taxes (including value-added tax) and other public taxes;

		7.6.3	credit vouchers or repayments granted for
returns (in each case, regardless of the grounds);

		7.6.4	volume discounts, which will only be applied
in retrospect, after a specific volume has been reached; and

		7.6.5	the reagent rental portion of the Application
Cartridges sales price for the hardware on which the Application Cartridges run.

		7.7	If the Purchaser itself uses the Gyronimo
Platform Analyzers commercially as and to the extent described in Clause 7.2, and also sells them, “Net Sales Revenue”
as defined in this Agreement shall mean the gross amounts invoiced for the Gyronimo Platform Analyzers sold by the Purchaser, minus
the following items:

		7.7.1	shipping costs;

		7.7.2	purchase taxes (including value-added tax) and other public taxes;

		7.7.3	credit vouchers or repayments granted for
returns (in each case, regardless of the grounds);

		7.7.4	volume discounts, which will only be applied
in retrospect, after a specific volume has been reached; and

		7.7.5	if the Analyzers are externally procured
from suppliers, the actual final net invoice amounts paid for the Analyzers (minus the items named above in Clauses 7.4.1 - 7.4.4)
shall be deducted.

		7.8	The payable Earn-Out amounts shall be distributed
to the Sellers in accordance with the Purchase Price Distribution Ratio.

		7.9	The licensing fees to be paid to the Sellers
from the Earn-Out shall be calculated retrospectively after expiry of a calendar quarter. Up until the maximum Earn-Out amount
is reached, the Purchaser agrees to inform the Sellers, within two months of the end of each calendar quarter, of the total amount
of the net sales revenue from the Gyronimo Platform Application Cartridges and/or Analyzers during each calendar quarter. In the
case of differences of opinion regarding the correctness of the notice, 

 

    	11 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

each
of the Sellers shall have the right to have the Purchaser’s accounting verified by an auditor to be chosen by the Seller
and obligated to maintain confidentiality. The Seller ordering the verification shall bear the costs associated with it. If the
auditor finds a deviance of more than [***]% from the license amount
communicated, which amount also simultaneously exceeds EUR [***], the
Purchaser shall bear the costs of the auditor provided that they are reasonable.

 

 

		8.	COMMERCIALIZATION

		8.1	The Purchaser shall be obligated to use
the assets it acquires, to make economically reasonable efforts to further develop the Gyronimo Platform, and to manufacture, market,
sell, or otherwise commercialize the Application Cartridges (hereinafter, referred to collectively as “to commercialize”
or as “Commercialization”). When determining the economic reasonableness of commercialization, the financial
situation, the personnel resources, the strategic orientation, the Purchaser’s other ongoing development projects and other
projects (in particular in comparison to the development stage and costs of the Gyronimo Platform), and the other products the
Purchaser markets, among other things, must be taken into consideration. The required investment, time to market, the Gyronimo
Platform’s expected competitive advantage, and the expected return on investment must also be taken into account when assessing
economic reasonableness. After the end of each fiscal year, the Purchaser shall inform the Sellers of the status of development
and commercialization.

		8.2	If, for whatever reason, the Purchaser should decide:

 

		8.2.1	not to further develop the Gyronimo Platform
and/or not to commercialize it after further developing it and/or

		8.2.2	not to manufacture, market, sell, or otherwise
commercialize the Application Cartridges

(“Decision
not to Commercialize”), it shall inform the Sellers of this immediately and no later than three (3) months after making
such a decision.

		8.3	If it makes a Decision not to Commercialize,
the Purchaser shall offer the Purchased Assets to the Sellers in their then-existing or further-developed form at market value.
In the case of a dispute, this value shall be determined by an external expert. This offer

 

    	12 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

must
then be accepted by the Sellers, collectively or individually, within a maximum deadline of 90 days.

		8.4	If, within [***]
years of the Execution Date, (i) Milestone I has not been achieved and (ii)
the Purchaser has initiated licensing and/or partnering negotiations with third parties regarding possible further development
and commercialization, the Purchaser shall be obligated to reach agreement with the Sellers in good faith, and in consideration
of the criteria in Clause 8.1 above in particular, regarding whether a Decision not to Commercialize should be made.

		8.5	The Parties shall not interpret provisions
of this Clause 8 as a preemption right in favor of the Sellers, but rather as only applying in the case where the Purchaser, on
the basis of its assessment of its commercialization, definitively decides that commercialization would not be economically reasonable
and also decides not to make use of the Purchased Assets via possible future licensing or a possible future sale to third parties.

 

 

II.             
TRANSFER OF THE ASSETS

9.            
TRANSFER OF THE ASSETS

		9.1	The Sellers shall provide the Purchaser
with updated and final versions of Annexes 2.2.1 to 2.2.3 eight days prior to the Execution Date (hereinafter, the “Updated
Annexes”). The Parties shall mutually and amicably verify the accuracy of the Updated Annexes. If the Purchaser informs
the Sellers in writing no later than one Banking Day prior to the Execution Date that it has identified specific assets in the
Updated Annexes that are not part of the Purchased Assets, these assets shall not be sold and transferred with the others, and
this shall not have an effect on the Purchase Price.

		9.2	To the extent that the Acquired Assets are
goods in the sense of the BGB [Germany Civil Code] or material assets, the Sellers agree to transfer ownership of the assets within
the Purchased Assets to the Purchaser on the Execution Date via creation of direct or indirect possession pursuant to §§
929 ff. BGB. If assets within the Purchased Assets are directly possessed by third parties, or if third parties have indirect possession
of these assets, the Sellers shall surrender the claims for restitution

 

    	13 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

against
these third parties to the Purchaser, who shall assume them, with effect as of the Execution Date. To the extent that transfer
of the Purchased Assets is not already effective based on this Agreement, the Sellers hereby undertake to immediately make any
additional declarations required to effect this transfer.

		9.3	The Sellers and the Purchaser agree that
ownership of the Acquired Assets transferred pursuant to Clauses 9.1 and 9.2 as of the Execution Date shall be transferred to the
Purchaser. If the Sellers have obtained a substitute of any kind for assets that are no longer available as of the Execution Date,
this substitute shall also be part of the Purchased Assets and shall be included in the transfer pursuant to Clause 9.2.

		9.4	To the extent that the Acquired Assets
are intangible assets and/or rights, the Sellers hereby transfer or surrender these assets and/or rights to the Purchaser effective
on the Execution Date; the Purchaser hereby accepts this transfer or surrender.

		9.5	The Sellers hereby agree to the transfer
of the intangible assets and/or property rights specified in Clause 2.2.2 to the Purchaser or a third party appointed by the Purchaser
and agree to provide the Purchaser with the documents required for this purpose, to provide all required signatures, to take all
required measures, and to do their best to support the Purchaser during the transfer.

		9.6	The benefits and burdens, as well as the
risk of accidental loss or deterioration of the Acquired Assets to be transferred pursuant to Clauses 9.1 to 9.4, are transferred
to the Purchaser effective as of the transfer of possession, otherwise – i.e., if transfer of possession is excluded due
to the nature of the Acquired Assets – effective as of the Execution Date. The provisions of § 287 BGB shall not be
affected by this. If a transfer of individual assets is, for any reason, not possible on the Execution Date, the Sellers shall
grant the Purchaser the greatest possible usage rights, to whit – and to the extent possible – transferable, sub-licensable,
worldwide, and exclusive usage rights. The granting of usage rights under Sentence 2 is also included in the Purchase Price. The
Sellers are, however, not released from their duty to transfer the assets unless this Agreement expressly foresees another solution.

 

    	14 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		9.7	Clause 12 shall also apply to the transfer
of the Gyronimo Platform technology, in particular the know-how associated with it.

 

		10.	EMPLOYEES

If
(i) the employment agreements of individual employees of the Sellers should unexpectedly be transferred to the Purchaser due to
execution of the Technology Purchase Agreement pursuant to § 613a BGB, without the Purchaser’s having previously agreed
to this in writing or having used their work voluntarily, in particular to avoid compulsory execution measures, or if (ii) employees
of the Sellers request that their employment agreements be transferred, the following shall apply:

		10.1	The Purchaser shall inform the Seller that
was the previous employer of the transferring employee of the assertion of such claims. The Purchaser shall reach agreement with
the Seller that was the previous employer of the transferring employee regarding the content and strategy of a defense, and the
Seller that was the previous employer of the transferring employee shall provide the Purchaser with support in its defense against
the claims.

When
defending against such claims, the Purchaser shall – to the extent legally possible and economically reasonable – attempt
as a matter of principle to amicably end the employment agreements in question in conjunction with the Seller that was the previous
employer of the transferring employee.

		10.2	The Seller that was the previous employer
of the transferring employee shall fully indemnify the Purchaser from all ensuing follow-up costs or reimburse the Purchaser for
them. These follow-up costs shall in particular include:

		10.2.1	continued payment of gross remuneration
and social security contributions, etc., for the period from the Execution Date to the point in time when the employment agreement
can first be (effectively) terminated after the employee has notified the Purchaser of his/her claim to transfer his/her employment
agreement;

		10.2.2	the settlement that is paid as of termination
of the employment agreement or to bring its termination about;

10.2.3       any
claims for employee invention compensation;

		10.2.4	reasonable costs, which may exceed those foreseen in the RVG [German Attorney
Compensation Act], for a legal defense by the law firm the Purchaser

 

    	15 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

also
engages for other labor law disputes, or by a comparable law firm, plus court and other legal expenses.

		10.3	The Purchaser shall work constructively together with the Seller that was
the previous employer of the transferring employee as part of its duty to reduce damages under § 254 BGB so as to reduce to
the extent possible the liability of the Seller that was the previous employer of the transferring employee for the above-arranged
assumptions of costs.

 

11.       CONDUCT UP TO THE EXECUTION DATE

		11.1	From the day on which this Agreement is
signed and up to the Execution Date, the Sellers shall be obligated:

		11.1.1	to continue work on the Purchased Assets with the care of a prudent businessman
and in agreement with current business practice as part of ordinary operations;

		11.1.2	not to undertake any actions or fail to undertake any required actions if
such conduct deviates significantly from the Sellers’ previous business practice as revealed in the Purchaser’s due
diligence and presented in the Warranties, unless the Purchaser agrees to the acts or failures to act in question; and

		11.1.3	to inform the Purchaser immediately in writing of any unusual operating
circumstances that affect the Purchased Assets.

 

12.       TECHNOLOGY
TRANSFER

		12.  1	The Sellers shall undertake to perform
the acts and services definitively specified in this Clause 12 and in Annex 12.1 after the Execution Date and to
transfer the specified information, documents, and materials in order to guarantee the transfer of the Gyronimo Platform Technology
as it exists as of the Execution Date (“Technology Transfer Services”).

		12 .2	The Parties shall begin to perform the Technology Transfer Services immediately
after the Execution Date, and they shall do their best to conclude the Technology Transfer Services as quickly as possible, and
no later than within 12 months after the Execution Date.

		12.3	The Parties agree that, in order to execute
the Technology Transfer, not only must the Acquired Assets be transferred, but 

 

    	16 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

 

 

also
the comprehensive instruction, training, and advising of the Purchaser in the form of a service, which is described in detail in
Annex 12.1. The instruction, training, and advising need not, however, be actually successful.

		12.3.1	The Sellers undertake to do their best to
introduce the Purchaser to the Gyronimo Platform and to the Acquired Assets as defined in Clauses 2.2.1 and 2.2.2, and to provide
the Purchaser’s employees with comprehensive training at the Purchaser’s headquarters, or at another location agreed
to by the Parties. For this purpose, the Sellers shall, after consulting the Purchaser, send a sufficient number of knowledgeable
persons and qualified and experienced employees (hereinafter, "Knowledgeable Persons") for a period of two weeks
to the Purchaser’s headquarters, or to another location agreed to by the Parties, during the first and second months after
the Execution Date, who shall instruct the Purchaser’s employees on the Gyronimo Platform. The Knowledgeable Persons shall
be the Seller employees named in Annex 12.3.l.

		12.3.2	If the Purchaser should
request it, the Sellers shall be willing to conduct other trainings. The Parties agree to a daily rate of EUR [***] for
each Seller employee who conducts such training.

		12.3.3	The Sellers declare that, during the first
12 months after the Execution Date, they are willing to provide the Purchaser with support by answering technical or regulatory
questions if the information and knowledge in question was already available as of the Execution Date. The Sellers shall not, however,
have an obligation to conduct additional research, provide additional information, or do additional design or development. No separate
compensation shall be paid for this support unless answering these questions requires more than 200 man-days. If additional services
are provided, they shall be remunerated pursuant to the compensation schedule in Clause 12.3.2.

		12.4	The Sellers shall bear all costs associated
with Technology Transfer measures (with the exception of any Purchaser employee travel and lodging expenses). These costs have
already been included in the Purchase Price pursuant to Clause 5.1 unless another arrangement is made in this Clause 12.

		12.5	The Technology Transfer shall be concluded
when the Sellers have transferred the Acquired Assets and have completely executed the measures specified in Annex 12.

 

    	17 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

The
Purchaser must call for the Technology Transfer Services within 12 months of the Execution Date, and do so with sufficient advance
notice of at least 10 working days so that they can be performed by the 12-month deadline. If the Sellers delay performance despite
receiving timely notice, they shall perform the services in question after expiry of the 12-month deadline.

 

III. GRANT-BACK

 

 

		13.	CARVE-OUT

		13.1	The Purchaser hereby grants the Sellers,
effective as of the Execution Date, and free of charge, a non-transferable, exclusive, irrevocable, worldwide license to use the
Gyronimo Platform intangible assets specified in Clause 2.2.2, and the Gyronimo know-how, in the areas of dental testing and food
(including drinking water) and environmental (including water) safety testing (the “Carve Out Field”). The license
shall include the right to grant sub-licenses. The Sellers shall guarantee that any sublicensees observe the arrangements in this
Agreement. The license granted below shall not obligate the Purchaser to maintain the property rights acquired with this Agreement,
to continue to make property rights applications, or to keep acquired know-how confidential. The Purchaser shall, however, inform
the Sellers in a timely manner if it should intend to abandon the property rights acquired so that the Sellers can take them over
and continue them. In this case, the Purchaser shall, free of charge, grant a transferable, exclusive, irrevocable, worldwide,
and sub-licensable license to the property rights in question for all areas outside the Carve-Out Field.

		13.2	The Sellers shall also receive, free of
charge, a non-exclusive, non-transferable, irrevocable, worldwide license to use the patent family “Method for determining
a property of a starting sample” (the so-called “Algorithm Patent”: EP 3 020 827; PCT/EP2015/076544)
for the purposes of their own internal research, including outside the Carve-Out Field.

		13.3	The Purchaser shall be willing to perform
services for the Sellers in the Carve-Out Field, to manufacture Gyronimo Platform Analyzers, Application Cartridges, and Assays
for use in the Carve-Out Field, and to label them with the brand and trade names the Sellers 

 

    	18 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

sell
as their own products in their own name. The Sellers shall, to the extent legally allowable, be the legal manufacturer of these
products and shall be solely responsible for these products, product development, clinical validation, regulatory issues and approvals,
and product liability. The details of such a delivery and service provision relationship shall be specified in a separate agreement.
However, the Parties shall not be obligated to enter into such an agreement.

 

 IV. THE SELLERS’ LIABILITY

 

		14.	THE SELLERS’ WARRANTY

		14.1	The Sellers shall individually give the
Purchaser independent and autonomous warranties, each of which shall have effect on its own, pursuant to § 311 Para. 1 BGB
(the “Warranties”) that the declarations made in Annex 14.1 are complete and accurate as of the
day on which this Agreement is signed. To the extent that the warranties regard the existence or non-existence of certain circumstances
(warranties of existence), these Warranties shall also be made effective as of the Execution Date.

		14.2	The Parties agree that the Warranties in
Annex 14.1 do not represent warranties of the characteristics of goods as defined in § 443 BGB, or of an agreement
on such characteristics pursuant to § 434 Para. 1 BGB. For this reason, the Parties agree that § 444 BGB shall not apply
to any of the Warranties.

		14.3	Warranties in Annex 14.1 that
are based on the knowledge or lack of knowledge of one of the Sellers (in particular as expressed in the phrase “to the best
of our knowledge”) are also infringed if the respective Seller had no knowledge of the infringement of the Warranty in question
due to grossly negligent conduct. This shall not apply to Warranties based explicitly and exclusively on the Sellers’ positive
knowledge. The knowledge and grossly negligent conduct of the persons named in Annex 14.3 Part l shall be imputed
to Systec, and the knowledge and grossly negligent conduct of the persons named in Annex 14.3 Part 2 shall be imputed
to Carpegen.

		14.4	Warranties based on the knowledge or lack
of knowledge of the Sellers also apply when given with effect as of the Execution Date if the Sellers have not informed the Purchaser
in writing of a modification in the circumstances underlying these Warranties prior to the Execution Date that leads the original
statements made to be incorrect or incomplete (hereinafter, the “Modified Circumstances”). If the Sellers have
informed the Purchaser of Modified Circumstances, the Parties shall, with effect

 

    	19 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

as
of the Execution Date, do their best to agree to modify this Agreement so that it contains an economically reasonable distribution
of risk among the Parties for the Modified Circumstances. If the Parties cannot reach such an agreement within four weeks of notice
by the Sellers of the Modified Circumstances, the Purchaser shall have the right to withdraw from this Agreement.

		14.5	The Purchaser recognizes that – to
the extent not contained in the Warranties pursuant to Clause 14.l – the Sellers have not made any Promises or Warranties
for the correctness or completeness of projections, estimates, or budgets that have been made available to the Purchaser or its
advisors during the sale process. The Sellers shall in particular accept no liability for the technical feasibility of the Gyronimo
Platform, serial production, future revenue estimates, cash flows, or the results of future transactions with the Gyronimo Platform.

		14.6	If one of the Warranties made by the Sellers
shall, in whole or in part, prove to be incorrect, incomplete, or not maintained (hereinafter, the “Warranty Infringement”),
the Sellers shall be obligated to create circumstances that place the Purchaser in the position it would be in if the Warranties
were overall accurate and complete (hereinafter, the “Contractual Circumstances”). To this end, the Purchaser
shall inform the Sellers in writing of the actual or possible infringement of the Warranty, describe the circumstances underlying
the Warranty Infringement, and, to the extent possible, communicate the estimated damages amount. In addition, in its notice of
Warranty Infringement pursuant to Sentence 2, the Purchaser shall give the Sellers a reasonable deadline by which to create the
Contractual Circumstances.

		14.7	No deadline pursuant to Clause 14.6 Sentence
3 need be set if creation of the Contractual Circumstances is legally or de facto impossible, economically unreasonable
from an objective point of view, or definitively rejected by the Sellers. In such a case, and also if the deadline set by the Purchaser
expires and the Contractual Circumstances have not been created, the Sellers shall be obligated, at the discretion of the Purchaser,
to pay the Purchaser damage compensation in cash pursuant to §§ 249 ff. BGB, although they shall not owe compensation
for lost profits or consequential damages.

		14.8	The Purchaser’s claims under Clause
14 (hereinafter, the “Warranty Claims”) become time-barred as follows:

 

		14.8.1	Warranty Claims based on infringement of Warranties
pursuant to Annex 14.1 No. 1 and also Nos. 2.1, 2.2, 2.4, and 5 shall become time-barred four years after the Execution
Date.

 

    	20 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

		14.8.2	All other Warranty Claims shall become time-barred
two years after the Execution Date.

		14.8.3	Time-barring of the Purchaser’s Warranty
Claims shall be suspended by timely notice of a Warranty Infringement pursuant to Clause 14.6 Sentence 2. The suspension shall
end:

		(a)	three months after notice of Warranty Infringement
pursuant to Sentence 1 if the Sellers have not yet declared their willingness to negotiate the Warranty Infringement notified by
the Purchaser; or

		(b)	three months after one Party notifies the
other that negotiations of the Warranty Infringement notified have ended;

(c)       §
203 BGB shall thus be excluded.

		14.9	The Purchaser shall have the right to deduct
Warranty Claims from the Sellers’ claims to payment of the Additional Purchase Price Milestones and/or Earn-Out.

 

		15.	LIMITATION OF LIABILITY

		15.1	Clause 14 above definitively governs the
Sellers’ Warranties and the Purchaser claims that arise from a Warranty Infringement. With the exception of rights in the
case of malicious conduct by the Sellers, all the Purchaser’s other contractual and legal rights in connection with the Sellers’
Warranties are excluded. The Purchaser’s claims due to the Sellers’ infringement of other provisions in this Agreement
shall remain unaffected.

		15.2	The Purchaser may only assert Warranty Claims
if, in the case of a Warranty Infringement, the following conditions are met:

		15.2.1	the individual Warranty Claim must exceed EUR [***];
and

		15.2.2	the individual Warranty Claim or the sum of the Warranty Claims, provided
that each individual Warranty Claim exceeds the amount specified in Clause 15.2.1, exceeds EUR [***] (hereinafter, the “Allowed
Amount”).

In
this case, the Sellers shall be obligated under this Agreement to pay the Purchaser the full amount of the damages pursuant to
Clauses 14.6 and 14.7, including the amount falling within the Allowed Amount. If the damages on which a Warranty Claim is based
fall below the amount specified in Clause 15.2.1,

 

    	21 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

but,
due to the infringement of the same Warranty, the Purchaser suffers a number of comparable damages (hereinafter, the “Serial
Damages”), the Serial Damages shall be totaled together as a Guarantee Infringement.

		15.3	Each of the Sellers shall only have liability
for the Purchaser’s Warranty Claims up to the full amount of its share of the Provisional Purchase Price.

		15.4	The Purchaser shall not have the right
to assert Warranty Claims if and to the extent that it was aware of the facts and circumstances underlying the Warranty Claim in
question when this Agreement was concluded. § 442 Para. 1 Sentence 2 BGB and § 377 HGB [Germany Commercial Code] shall
be excluded. All information shall be considered as known to the Purchaser that was disclosed in the data room, in this Agreement,
or in its annexes, or that was provided to the Purchaser or its advisors in written form, in such a complete manner that (i) the
circumstances on which the claims are based would have been evident to any reasonable reader without the need of additional research
and (ii) all significant aspects of the disclosure were accurate and not misleading. A data room CD is attached to this Agreement
as evidence of the content of the data room.

		15.5	Claims may be asserted against the Sellers
only one time for the same damages, even if multiple Warranties have been infringed. In addition, the Sellers shall not be liable
to the extent that:

		15.5.1	the Purchaser receives compensation for damages
from third parties, including insurance companies;

		15.5.2	the Purchaser has not fulfilled its obligation
to reduce damages pursuant to § 254 BGB;

		15.5.3	the Purchaser has already otherwise been compensated
for damages (no double-dipping) or received other benefits (benefit sharing); or

		15.5.4	the claim is based on a modification of legal provisions that occurred
after this Agreement was signed.

		15.6	In deviation from the principal of joint
and several liability otherwise applicable to all obligations under this Agreement, the Sellers shall be individually responsible
in the case of a Warranty Infringement and/or breach of this Agreement if the Warranty Infringement or the breach of this Agreement
can be allocated to one of them individually. Such an allocation shall be suspected:

		15.6.1	if and to the extent that the breach of
this Agreement was demonstrably committed by only one of the Sellers;

		15.6.2	if and to the extent that assets leading to
the Warranty Infringement can be allocated to one specific Seller pursuant to the general allocation of assets to the respective

 

    	22 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Sellers in and pursuant
to Annex 15.6;

		15.6.3	the Warranty Infringement can be allocated
to one specific Seller in light of its awareness or knowledge of liability-relevant circumstances (each Seller shall only be liable
“to the best of its knowledge”); and

		15.6.4	the Sellers immediately, and no later than
within three (3) months of being notified by the Purchaser, inform the Purchaser truthfully (i.e., in accordance with actual liability
for the Warranty Infringement) and jointly of an allocation to one of the Sellers.

		15.7	To the extent that joint and several liability
by the Sellers is expressly excluded under this Agreement, infringements by the respective other Seller shall not be included.

		15.8	The Sellers shall not have the right to
refuse to satisfy Purchaser Warranty Claims by referring to any damage or compensation claims the Purchaser might have against
third parties in connection with the Warranty Infringement asserted (hereinafter, “Claims against Third Parties”).
If the Sellers have satisfied the Purchaser’s Warranty Claims under this Agreement, the Purchaser shall undertake to surrender
the Claims against Third Parties to the Sellers, to the extent that this is legally allowed. If surrender of Claims against Third
Parties is not legally allowed, the Purchaser shall be obligated, at the instructions of the Sellers, to assert the Claims against
Third Parties, with reimbursement of all costs and expenses connected with assertion of the Claims against Third Parties, and to
cede all third party payments to satisfy Claims against Third Parties to the Sellers.

 

 

16. THIRD-PARTY
CLAIMS PROCEDURE

16.1 If third parties make
claims against the Purchaser in connection with a possible Warranty Infringement (hereinafter, Third-Party Claims), the
Purchaser shall

16.1.1 give the Sellers
an opportunity to defend themselves against such claims on behalf of the Purchaser at the Sellers’ costs, initiate all appropriate
procedures to this end, and coordinate such defense measures, and specifically let the Sellers during this process

(a) take part in and manage
all hearings and written correspondence with the third party, and

    	23 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

(b) appoint an attorney to defend against the
Third-Party Claims in the Purchaser’s name;

16.1.2 without a prior written consent of the
Sellers, neither recognize nor settle the claims, nor approve recognition or settlement, as long as such recognition or settlement
could lead to liability of the Sellers under this Agreement;

16.1.3 grant the Sellers and the Sellers’
advisors bound by the professional confidentiality duty, against compensation of reasonable costs, access during normal working
hours to all business acts and documents pertaining to the Purchased Assets available to the Purchaser and allow the Sellers and
the Sellers’ advisors bound by the professional confidentiality duty to a reasonable extent to obtain advice from the management,
employees and representatives of the Purchaser, as long as this does not disrupt the Purchaser’s operations.

16.2 The costs and expenses incurred by the
Purchaser in connection with defense against Third-Party Claims represent damages of the Purchaser and the Purchaser is entitled
to their compensation under Clauses 14 and 15, as long as the costs and expenses shall not be borne by the third party according
to the outcome of the procedure. The Sellers shall further bear their own costs and expenses that arise in the course of the defense
against the Third-Party Claims, as long as the costs and expenses shall not be borne by the third party according to the outcome
of the procedure.

17. INDEMNIFICATIONS

17.1 Each of the Sellers shall bear its own
taxes (hereinafter referred to in this Clause 17.1 as Taxes) arising in connection with realization of any sales profit
under this agreement. Furthermore, the Sellers are obligated to compensate the Purchaser for all outlays and hold it harmless of
all liabilities that the Purchaser incurs as the result of enforcement of taxes related to the Purchased Assets against the Purchaser
by the responsible tax office under Clause 75 of the German Fiscal Code, which taxes are attributable to the time period prior
to the Execution Date. Taxes within the meaning of this Clause 17.1 include all taxes and additional tax payments within the meaning
of Clause 3 of the German Fiscal Code. Social insurance payments and other deductions (including fines) and the respective deduction
under foreign laws (in all cases including deductions applied as tax payments) and liability for the above said taxes.

 

    	24 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

17.2 The Sellers are obligated to compensate
the Purchaser for all outlays and hold it harmless of all liabilities that the Purchaser incurs in connection with the following
aspects, as long as the events underlying the compensation claim are invoked against the Sellers within four (4) years after the
Execution Date:

17.2.1 A contract partner of the Sellers brings
claims against the Purchaser with respect to which the Purchaser did not undertake the respective obligations of the Sellers under
this Agreement.

17.2.2. Sponsors of the Sellers produce claims
against the Purchaser for repayment of the support paid to or for the benefit of the Sellers.

17.2.3 The Sellers’ employees produce
claims to inventor compensation with respect to the patents and patent applications listed in Annex 2.2.2(a).

17.3 The Purchaser shall inform the Sellers
in an appropriate manner if third parties produce claims against the Purchaser based on the circumstances described in Clause 17.2.

V. ADDITIONAL
PROVISIONS

18. NON-COMPETITION AND NON-SOLICITATION

18.1 Each of the Sellers undertakes, during
three years following the Execution Date, not to establish a company and not to participate in a company that engages in business
competing with the Gyronimo platform for use outside the Carve Out Field, and not to themselves engage in business activities or
development measures in connection with the Gyronimo platform outside the Carve Out Field or with another cartridge-based point-of-care
diagnostic platform. The Seller is aware that Carpegen is a cooperation partner of the joint [***] project ([***]). The obligation
under sentence 1 does not apply in this respect, as long as the [***] project of the Sellers supported within the scope the LifeSciences.NRW
lead market competition does not target development of a cartridge-based sample-to-answer point-of-care capable diagnostic platform.
Should the [***] group have or be developing plans to target development of a cartridge-based sample-to-answer point-of-care capable
diagnostic platform with the project, Carpegen will withhold its approval of such plans for the duration of the non-competition
clause. The obligation under sentence 1 is limited to the European Union (for the sake of clarity, including the United Kingdom),
Switzerland, USA, and China. The Sellers further undertake not to engage in prohibited activities through a third country in the
geographical area covered by this Clause 18.1. An exception from the obligation under sentence 1 is acquisition of shares in listed
companies up to a 5% share of the respective share capital.

18.2 The Purchaser shall not solicit during
two years following the Execution Date any current executives or employees of the Sellers, which limitation does not apply to hiring
employees whose employment had been ended by the Sellers before that, who had quit their employment of their free will before the
talks regarding employment with the Purchaser commenced or had agreed to an amicable release, or who apply for employment with
the Seller without solicitation of the latter.

19. CONFIDENTIALITY AND PUBLICATIONS

19.1 The parties undertake to keep in confidence
all information, and especially the trade and business secrets, of the other party and not to disclose, either directly or indirectly,
such information and secrets to third parties or cause, support or conceal their disclosure by third parties, and not to use such
information

    	25 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

or secrets for their own purposes. The confidentiality
duty under sentence 1 shall survive termination by any party of this Agreement for all parties. Such confidentiality duty shall
not apply if

19.1.1 the respective information became publicly
known through no fault of the respective party; or

19.1.2 based on mandatory legal provisions
or order of a court or an authority, the respective party is obligated to make a disclosure, and in such case the party obligated
to make a disclosure shall inform the other party in advance and limit the disclosure to the scope required by the law, the court
order or the order of an authority; or

19.1.3 the other parties had previously given
their written consent to disclosure.

19.2 In a similar way, the parties are obligated
to keep the contents of this Agreement in confidence, unless the respective facts are publicly known or their public disclosure
is prescribed by the law, the order of a court or an authority, or is required for the purposes of calculation of employee invention
compensation to the current or former employees. In such case the parties shall inform each other in advance and limit the disclosure
to the scope required by the law, the court order or the order of an authority.

19.3 The Sellers are specifically obligated
to keep all information regarding the Gyronimo platform, especially the know-how assigned under Clause 2.2.3, in confidence and
not to disclose, either directly or indirectly, such information to third parties or cause, support or conceal its disclosure by
third parties, and not to use such information for purposes other than license under Clause 13.1. Release of this information under
a license permitted under Clause 13.1 requires that the Sellers obligate the sub-licensee to maintain confidentiality in the scope
of this Clause 19. Exceptions under Clauses 19.1.1 to 19.1.3 apply accordingly. The Purchaser can use the Purchased Assets at its
discretion and is not obligated to keep it in confidence. The Purchaser is specifically obligated to keep the know-how licensed
under Clause 2.4 in confidence and not to disclose such information, either directly or indirectly, to third parties or cause,
support or conceal its disclosure by third parties, and not to use such information for purposes other than license under Clause
2.4. Release of this information under a license permitted under Clause 6 requires that the Sellers obligate the sub-licensee to
maintain confidentiality in the scope of this Clause 19. Exceptions under Clauses 19.1.1 to 19.1.3 apply accordingly. The Sellers
can use the know-how licensed under Clause 2.4 at their discretion and are not obligated to keep it in confidence.

19.4 The parties shall issue a joint press
release in connection with this Agreement, whose final agreed version is provided in Annex 19.4. Further announcements
regarding transactions performed under this Agreement shall only be made if such announcement is legally prescribed, and in such
case the contents of the announcement shall be agreed with the other parties.

 

    	26 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

20. COMPLIANCE

20.1 With respect to entering into a financing
agreement with the European Investment Bank (hereinafter the EIB) planned by the Purchaser, the Sellers undertake, including
by an agreement in favor of third parties with respect to the EIB,

20.1.1 to inform the EIB on all grounded objections,
claims or other information known to the respective Seller about Illegal Activities in connection with the project;

20.1.2 to document in writing this Technology
Purchase Agreement, its performance and all financial transactions and investments in connection with the project and to archive
the respective documents (hereinafter the Project Documentation) with due care; and

20.1.3 in case of alleged Illegal Activities,
to grant the EIB access to the Project Documentation, to the extent legally permissible, and to permit the making of copies.

20.2 Illegal Activities in the context
of this Clause 20 specifically include the following prosecutable activities: tax evasion, fraud, deceit, bribery, procedural fraud,
coercion, fictitious transactions, obstruction of justice, money laundering, financing of terrorism, organized crime or any other
action prosecutable under the respective criminal law that affects the financial interests of the EU.

20.3 Project in the context of this Clause
20 means the Gyronimo platform, the Unyvero platform or any other cartridge-based sample-to-answer point-of-care capable platform
that is developed and/or marketed by the Purchaser.

21. DISCLOSURES
AND DECLARATIONS

All disclosures and declarations produced under
this Agreement or in connection with this Agreement shall only be valid if made in writing and delivered to the recipient described
below in person, by certified mail, by courier, by telefax or as a signed and scanned document per e-mail. Disclosures and declarations
shall only be legally binding on a party if they are sent to the following address, unless the party has provided a different address
in writing to the other party:

    	27 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

For Systec:

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

with a copy to: Osborne Clarke

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

For Carpegen:

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

with a copy to: Osborne Clarke

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

For the Purchaser: Curetis GmbH, Management

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

 

 

    	28 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

 

with a copy to: Curetis GmbH, Legal Department

Address:       [***]

Tel.:       [***]

Fax:       [***]

E-mail:       [***]

Att.:       [***]

22. COSTS

22.1 Each party shall bear its own costs and
expenses in connection with the preparation, negotiation and performance of this Agreement, unless expressly provided otherwise
in the Agreement.

22.2 Other provisions of this Agreement regarding
responsibility for costs shall remain unaffected.

23. FINAL PROVISIONS

23.1 This Agreement, together with its Annexes,
contains the entire agreement and understanding among the contracting parties with respect to its subject. It replaces all previous
agreements, oral or written declarations of intent and other legally binding and non-binding arrangements between the parties with
respect to the subject of the Agreement.

23.2 The Annexes to this Agreement constitute
an important integral part of the Agreement. In case of deviations between an Annex and a provision of this Agreement, the provision
of the Agreement shall prevail. Headings of this Agreement are provided solely for convenience and do not affect the interpretation
of the Agreement.

23.3 Changes to and amendments of this Agreement
shall only be valid if made in writing, as long as the law does not impose stricter requirements as to form. This clause shall
also apply to changes to and amendments of the written form requirement under sentence 1.

23.4 All disputes arising in connection with
this Agreement or its validity shall be definitively resolved according to the respective Arbitration Rules of the German Arbitration
Institute (DIS) without recourse to ordinary courts of law. The arbitration court shall consist of three (3) arbitration judges.
The venue of the arbitration proceeding shall be Stuttgart. The arbitration proceedings shall be conducted in German, but evidence
can also be produced in English. If mandatory law provisions require that a matter resulting from or in connection with this Agreement
or its performance be resolved in an ordinary court of law, then the venue shall be Stuttgart.

23.5 Should some provisions of this Agreement
be or become invalid or unenforceable in full or in part or should there be loopholes in this Agreement, this shall not affect
the validity of the other provisions. The invalid or unenforceable provision shall be substituted with a valid and enforceable
provision that reflects the meaning and purpose of the invalid or unenforceable provision. In the case of a loophole, the provision
shall be deemed to have been agreed that corresponds to what would have been agreed according to the contents and purpose of this
Agreement, had the matter been considered from the very beginning. This shall also apply if the invalidity of a provision results
from a measurement of performance or time governed by this Agreement; in such cases, the legally permissible measurement of performance
or time that most closely comes to the intended one shall be applied instead of the agreed measurement.

    	29 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

23.6 If provisions of this Agreement require
interpretation or additions, then such interpretation or additions shall be performed as closely as possible in line with the spirit,
contents and purpose of this Agreement. In such cases, the provisions shall apply that would have been agreed by the parties when
they were entering into this Agreement, had the parties recognized the need of interpretation or additions.

 

SIGNATURES

	Systec Elektronik und Software GmbH

                            

                           represented by:

                           /s/ Tilmann Wolter

                           Name: Tilmann Wolter

                           Title: CEO
	 	Carpegen GmbH

                            

                           represented by:

                           /s/ Antje Rötger

                           Name: Dr. Antje Rötger

                           Title: CEO

	 	 	 
	Curetis GmbH

         

         

        represented by:

        /s/ Oliver Schacht

        Name: Oliver Schacht

        Title: CEO
	 	Curetis GmbH

         

         

         

        /s/ Johannes Bacher

        Name: Johannes Bacher

        Title: COO

 

    	30 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

Frog Prince Project: Annexes to the Purchase
Agreement

	Annex 1.1	Commercial Register excerpt and shareholder list of Systec
	Annex 1.2	Commercial Register excerpt and shareholder list of Carpegen
	Annex 1.3	Commercial Register excerpt of Curetis
	Annex 2.2.1 (a)	CAD 3D models and technical drawings of devices and analyses
	Annex 2.2.1 (b)	Prototypes, prototype parts and test stands, as well as test equipment
	Annex 2.2.1 (c)	CAD 3D models and technical drawings of application cartridges
	Annex 2.2.2 (a)	Patents and patent applications 
	Annex 2.2.2 (b)	Trademarks
	Annex 2.2.2 (c)	Software
	Annex 2.2.3	Transferred know-how
	Annex 2.4	Exclusively licensed know-how for use in connection with Gyronimo
	Annex 2.5	Obligations to be assumed under BMBF projects
	Annex 7.4	Industrial property rights of third parties 
	Annex 12.1	Technology transfer performance
	Annex 12.3.1	Know-how carriers on the side of the Sellers for technology transfer
	Annex 14.1	Guarantees of the Sellers (including Annexes)
	Annex 14.3 Part 1	Relevant Systec persons

 
 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

	   Annex 14.3 Part 2	Relevant Carpegen persons
	Annex 15.6	General classification of the transferred assets and responsibilities to the respective Seller
	Annex 19.4	Press Release

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 1.1

Commercial Register excerpt
of Systec

[***]

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 1.2

Commercial Register excerpt
of Carpegen

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 1.3

Commercial Register excerpt
of Curetis GmbH

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.1 (a)

CAD 3D models and technical
drawings of devices and analyses

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.1 (b)

Prototypes, prototype
parts and test stands, as well as test equipment

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.1 (c)

CAD 3D models and technical
drawings of application cartridges

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.1 (d) Production
tools

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

Annex 2.2.2 (a)

Patents and patent applications

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.2 (b)

Trademarks and trademark
applications

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.2 (c)

Software

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.2.3

Gyronimo Know-how

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.4

Exclusively licensed
know-how

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.5

Obligations to be assumed
under BMBF projects

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 7.4

Identified industrial
property rights of third parties

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 12.1

Service obligations after
Execution Date

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 12.3.1

Know-how carriers on
the side of the Sellers for technology transfer

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 14.1

Guarantees of the Sellers

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annexes to guarantee
catalog (Annex 14.1)

Annex 2.4

Use rights

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.5

Aspects in which transfer
or use of Gyronimo know-how is not prohibited for the time period of at least five years following the Execution Date

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.6

No proof of destruction

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 2.8

Known industrial property
rights of third parties

(see CD ROM)

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 5.1

Support funds

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 5.3

Performance of obligations
towards sponsors

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 6.1

Legal disputes

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 14.3 Part 1

Relevant Systec persons

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 14.3 Part 2

Relevant Carpegen persons

[***]

 

    	 

    	 

    

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

Annex 15.6

General classification
of the transferred assets and responsibilities to the respective Seller

[***]

 

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

Annex 19.4

Press Release

Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec

 

- Gyronimo Platform offers rapid,
quantitative cartridge-based sample-to-answer molecular diagnostic testing

- Gyronimo to be fully integrated
into Unyvero Platform and suite of products

 

Amsterdam, the Netherlands, and Holzgerlingen, Germany, December
13, 2016 - Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer
of next-level molecular diagnostic solutions, today announced the acquisition of the real-time qPCR-based Gyronimo Platform from
Carpegen GmbH and Systec GmbH, joint owners of the platform.

 

The transaction allows Curetis to transform Unyvero into a uniquely
broad platform offering with capabilities ranging from rapid 1 hour testing for 10+ diagnostic targets to highly multiplexed syndromic
testing panels delivering results for over 100 diagnostic targets in 4 to 5 hours. Integrating Gyronimo into the Unyvero Platform
for infectious disease testing will also allow Curetis to significantly expand its product portfolio into novel application in
areas such as infection control, viral testing and CNS infections, as well as applications for immunocompromised patients.

 

Under the terms of the agreement, Curetis is acquiring all Gyronimo
Platform assets, including fully functional prototype systems and the entire intellectual property portfolio comprised of several
patent families pending and a key patent granted in the U.S., Canada and China already, and allowed in Europe. Curetis will also
obtain exclusive Gyronimo know-how and a non-exclusive license to background intellectual property and know-how. Curetis will be
granted exclusive worldwide rights to the platform, including the right to sublicense, partner or sell it, with an exemption for
Carpegen and Systec in dental testing as well as in environmental and food safety testing.

 

Curetis will make a one-time upfront payment of EUR 5.0 million
in cash. In addition, Carpegen and Systec are eligible for two discrete, one-time milestone payments upon platform and first cartridge
CE marking and FDA clearance, respectively, totaling up to EUR 2.5 million. There will also be the potential for a royalty-based
earn-out at an industry-typical mid-single digit percentage rate, up to a maximum of EUR 9 million.

 

Gyronimo offers rapid time to result (potentially as fast as 60
minutes), qualitative and, where needed, quantitative real-time PCR testing in a cartridge format that can provide up to 10 parallel
multiplex qPCR reactions from one sample. As such, it lends itself to medium multiplexing applications ranging from 10 to 30 diagnostic
targets. Curetis intends to fully and seamlessly integrate the Gyronimo Platform into its Unyvero Platform suite of products with
respect to system architecture, design, software and handling. In particular, the new Unyvero Module will leverage the unique capabilities
of the Unyvero Cockpit and Lysator for seamless workflow integration and flexible handling of very challenging and diverse native
patient samples. In addition, all-in-one stand-alone modules are envisaged for certain future applications.

 

Curetis will take over functional prototype instruments and cartridges,
and will complete the IVD development and industrialization as well as OEM manufacturing of systems and cartridge production. The
Company expects completion of development and CE IVD marking not before late 2018. COGS of the Gyronimo cartridges are expected
to be considerably lower than those for Unyvero Cartridges and other MDx multiplexing systems, opening up attractive commercial
opportunities in the medium multiplexing infectious disease testing market segment.

 

“We are truly excited about the transaction which offers us
an excellent opportunity to accelerate the growth and development of our Unyvero Platform with complementary and greatly expanding
characteristics,” said Dr. Oliver Schacht, CEO of Curetis. “Gyronimo’s advanced product development stage, its
speed, quantitation ability, low cost of goods and mid-range multiplexing features are unique. It is therefore a natural next step
in the development of our Unyvero Platform and we do not

 

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

intend to develop it as a separate system, but rather as an integral
and modular part of our overall Unyvero Solution. It expands and provides our product portfolio with a remarkable competitive edge,
i.e. an unmatched diagnostic bandwidth ideally suited for any particular clinical application from as few as 5 or 10, via 20 to
30, and up to over 100 markers. We believe that the platform will allow us to address additional infectious disease indications
in hospitals. It will significantly expand our market opportunity and provide us with the opportunity to double our peak sales
potential in the long run.”

 

„With Curetis, we have found the ideal partner to take the
Gyronimo Platform through the final stages of product development, industrialization, manufacturing and scale-up as well as global
commercialization,” said Dr. Antje Rötger, CEO of Carpegen GmbH. “We will benefit substantially from the ultimate
commercial success of the platform and we have retained certain areas that are of direct commercial interest to us, such as dental
testing and environmental and food safety testing. To this end, we have agreed that we may discuss a possible OEM partnership with
Curetis at a future point in time to obtain Gyronimo instruments and cartridges for our own commercial purposes. We are excited
to be working closely with Curetis on the smooth transfer of all assets and know-how in the coming months.”

 

„We have developed the Gyronimo Platform from the first idea
to its current stage as a fully functional and working prototype in a multi-year, close R&D collaboration and partnership with
Carpegen,” said Klaus-Gerd Schoeler, CTO of Systec GmbH. “Our teams are joint inventors of several core patents. We
believe that putting the platform into the hands of a more mature, fully integrated IVD company such as Curetis offers us a faster
and ultimately more successful and rewarding path to fully develop, leverage and commercialize the asset. We look forward to working
closely with the Curetis team in the coming months as we hand over all system development projects.”

 

At present, Curetis is marketing its Unyvero System and three application
cartridges for pneumonia, implant and tissue infections, bacteremia and the company has a fourth Application Cartridge for intra-abdominal
infections in late stages of development. Curetis’ broad development pipeline of additional application cartridges further
features applications to test for sepsis host response, urinary tract infections, cardiology-related infections and an extended
panel for respiratory tract infections.

 

 

###

 

 

Disclaimer

CAUTION - Investigational device.
Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available
for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero
product which may be sold at some future point in time in the U.S. have not yet been established.

 

###

 

 

About Curetis

Founded in 2007, Curetis is a molecular diagnostics
company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe
infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker
detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

 

To date, Curetis has raised EUR 44.3 million
in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has
entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart,
Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution
agreements covering many countries across Europe, the Middle East and Asia.

 

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

 

 

For further information, please visit www.curetis.com.

 

 

Legal Disclaimer

This document constitutes neither an
offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision
in Curetis.

The information contained in this press
release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness
of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained
in this press release whether as a result of new information, future events or for other reasons.

This press release includes statements that
are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the
use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”,
“expects”, “intends”, “may”, “will”, or “should”, and include statements
Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties
and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual
results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly
update or revise forward-looking statements, except as may be required by law.

 

    	 

    	 

    

 

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

Contact details

 

Curetis

Max-Eyth-Str. 42

71088 Holzgerlingen, Germany

Tel. +49 7031 49195-10

pr@curetis.com or ir@curetis.com

www.curetis.com - www.unyvero.com

 

International Media & Investor Inquiries

akampion

Dr. Ludger Wess / Ines-Regina Buth

Managing Partners

info@akampion.com

Tel. +49 40 88 16 59 64

Tel. +49 30 23 63 27 68

 

U.S. Media & Investor Inquiries

The Ruth Group

Lee Roth

lroth@theruthgroup.com

Tel. +1 646 536 7012Exhibit 10.39.1

Certain identified information has been excluded from this
exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates
that information has been redacted.

 

SERVICES FRAME AGREEMENT

between

Ares Genetics GmbH

Karl-Farkas Gasse 18

1030 Wien

Austria

(the “Service Provider/Institution”)

and

Sandoz International GmbH

Industriestrasse 25

D-83607 Holzkirchen

Germany

(“Sandoz”)

Effective Date:14 December 2018

Subject

Sandoz and Service Provider/Institution
hereinafter also referred to as “Parties” and each individually as “Party”.

		A.	This Services Frame Agreement (“Agreement”)
                                         shall form the framework of contractual conditions under which the Service Provider/Institution
                                         will perform for Sandoz and/or its Affiliates services in the field of molecular microbiology
                                         techniques combined with advanced bioinformatics and artificial intelligence approaches
                                         (the “Services”) as specified in work orders which shall be similar in fashion
                                         to the example work order outlined in Annex 1 and shall be executed by the Parties (or
                                         by the Service Provider/Institution, and an Affiliate of Sandoz) and shall expressly
                                         refer to this Agreement (“Work Orders”). The general scope of the Services
                                         shall be outlined in each Work Order which shall form an integral part of this Agreement.
                                         The Service Provider/Institution is regularly engaged in conducting the Services. The
                                         Services may involve one or more chemical compounds (each a “Study Material”)
                                         and/or actual and/or potential pharmaceutical products identified in the Work Order.
                                         Service Provider/Institution shall not perform any Services and/or research beyond the
                                         scope of the Work Order without the prior written consent of Sandoz.

		B.	For the purpose of this Agreement, “Affiliate”
                                         shall mean any corporation or other business entity controlled by, controlling or under
                                         common control with Sandoz. “Control” for the purposes of this definition
                                         shall mean direct or indirect beneficial ownership of fifty percent (50%) or more of
                                         the voting interest in an entity, or such other relationship as, in fact, constitutes
                                         actual control.

    	 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		C.	For the purpose of this Agreement, “Personal
                                         Data” shall mean any information (as defined by local Data Protection Legislation)
                                         relating to a identified or identifiable person; It includes without limitation electronic
                                         data and paper-based files that include such information, such as name, home address,
                                         office address, e-mail address, age, gender, family information, profession, education,
                                         professional affiliations, salary and credit card numbers.

		D.	The Service Provider/Institution shall
                                         perform the Services in accordance with this Agreement and the relevant Work Orders,
                                         in compliance with state-of-the-art scientific standards and laboratory practice.

		E.	The Service Provider/Institution warrants
                                         that its employees and collaborators will comply with its obligations under this Agreement.

		F.	The Service Provider/Institution warrants
                                         that its employees and subcontractors/agents will comply with its obligations under this
                                         Agreement.

		G.	If requested, Service Provider/Institution
                                         shall negotiate in good faith Quality Agreements with Sandoz and/or any of Sandoz’
                                         Affiliates. Service Provider/Institution represents and warrants that its performance
                                         hereunder, including without limits Service Provider/Institution’s provision of
                                         Services, shall be in accordance with any such Quality Agreement which shall become an
                                         integral part of this Agreement upon its/ their execution. For the avoidance of any doubts,
                                         any conflict between the provisions of this Agreement and any Quality Agreement shall
                                         be resolved in favour of this Agreement, except for conflicts that relate to quality
                                         assurance aspects, in which case the provisions of the relevant Quality Agreement shall
                                         prevail.

		1.	Term of this Agreement

This Agreement shall be deemed
effective as of the effective date written above and shall remain in effect for a period of three (3) years from that date unless
sooner terminated in accordance with the terms of this Agreement.

		2.	Termination

		2.1	Sandoz may terminate this Agreement
                                         and/or any Work Order at any time and for any reason, by giving written notice to the
                                         Service Provider/Institution with immediate effect. Unless Sandoz terminates any Work
                                         Order because of a breach by the Service Provider/Institution, in which case Sandoz shall
                                         owe the Service Provider/Institution no further obligations, Sandoz shall make payment
                                         to the Service Provider/Institution for all reasonable costs incurred or accrued in performing
                                         the Services prior to receipt of the notice of termination of the Work Order and not
                                         yet paid for by Sandoz.

    	2 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		2.2	This Agreement may be terminated by
                                         either Party at any time by notice in writing to the other Party with immediate effect
                                         in any of the following circumstances:

		(a)	if the other Party has breached
                                         any of its obligations hereunder and has failed to remedy such breach within 30 (thirty)
                                         days of receipt of notice in writing specifying the breach;

		(b)	if the other Party has gone into
                                         liquidation otherwise than for the purpose of amalgamation or reconstruction; or has
                                         had a receiver or manager appointed in respect of any of its assets; or has entered into
                                         any composition with its creditors; or

		(c)	if the other Party merges with
                                         a third party, or transfers beneficial ownership of more than fifty percent (50%) of
                                         its voting shares to a third Party.

		2.3	Upon any termination or expiration
                                         of this Agreement, all outstanding rights and obligations between the Parties arising
                                         from or in connection with this Agreement shall immediately terminate, except:

		(a)	any obligation that matured prior
                                         to the effective date of the termination or expiration;

		(b)	Sections 4 (Intellectual Property
                                         Rights), 5 (Confidentiality and Non-use), 9 (Taxes and Social Security Contributions),
                                         10 (Publications and Publicity), 12 (Retention of Materials Relating to Services), 16
                                         (Indemnification and Liability), 24 (Jurisdiction), 25 (Data Protection and Security);
                                         and

		(c)	any other provision which, by its
                                         terms, is understood to survive the termination or expiration of this Agreement.

		2.4	Termination of this Agreement shall
                                         be without prejudice to any claim or right of action of either Party against the other
                                         Party for any prior breach of this Agreement.

		2.5	Notwithstanding the foregoing, should
                                         any Work Order executed during the term of this Agreement require Services to be completed
                                         after the expiry or termination of this Agreement, the terms of this Agreement shall
                                         remain in effect with respect to such Work Order until the Work Order has been terminated
                                         or the Services thereunder have been completed.

		3.	Reports

		3.1	Unless the Work Order specifies more
                                         detailed reporting requirements, the Service Provider/Institution shall submit a final
                                         written report to Sandoz within 60 (sixty) days after the completion of the Services
                                         under a particular Work Order, describing the work performed, the results obtained, and
                                         the interpretation of results and all raw data (the “Final Report”).

    	3 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		3.2	The Service Provider/Institution warrants
                                         that each Final Report (and any other report specified in the Work Order) submitted to
                                         Sandoz is true, complete and correct and accurately reflects the result of the corresponding
                                         Services.

		4.	Intellectual Property Rights

		4.1	All data, information and documents
                                         provided to the Service Provider/Institution by or on behalf of Sandoz or its Affiliates
                                         in connection with this Agreement, whether in paper, oral, electronic or any other form,
                                         shall remain the sole property of Sandoz. The Service Provider/Institution shall acquire
                                         no rights therein.

		4.2	All intellectual property owned by
                                         or licensed to Service Provider/Institution prior to the Services as documented in Annex
                                         4 (the “Service Provider Background Intellectual Property”) and any
                                         improvements thereto shall remain the property of Service Provider/Institution or Service
                                         Provider/Institution’s licensor, as the case may be. Service Provider/Institution
                                         hereby grants Sandoz and its Affiliates a non-exclusive, irrevocable, perpetual, worldwide,
                                         royalty-free license to use the Service Provider Background Intellectual Property and
                                         any improvements thereto that is incorporated into, and/or necessary for the non-infringing
                                         use of any work or invention or any relating intellectual property rights with regard
                                         to a Work Order and/or the Results. “Non-infringing use” shall mean
                                         use that does not infringe any intellectual property other than the intellectual property
                                         owned by or licensed to Sandoz and its Affiliates.

		4.3	Except for Service Provider Background
                                         Intellectual Property as defined above, all materials, data, results, information, documents,
                                         reports, inventions (whether patentable or not), know-how and discoveries resulting from
                                         or arising out of the Services or developed by the Service Provider/Institution in connection
                                         with this Agreement and all intellectual property rights therein (the “Results”)
                                         are hereby assigned to and shall be the exclusive property of Sandoz and its Affiliates
                                         (or their designees) and may be used and/or transferred by Sandoz and its Affiliates
                                         for any purpose at their sole discretion with no further payment or other obligation
                                         to the Service Provider/Institution. Results shall include without limitation all compounds
                                         and derivatives obtained, generated or developed in connection with any Services. The
                                         Service Provider/Institution shall have no rights whatsoever in the Results. Notwithstanding
                                         the aforesaid, Service Provider may include the primary sequencing and antibiotic resistance
                                         data into “ARESdb” (it’s database used to get the project data).

		4.4	Except for Service Provider Background
                                         Intellectual Property as defined above and within the guard rails of German Employee
                                         Invention Law (“Arbeitnehmererfindungsgesetz”), the Service Provider/Institution
                                         agrees to cause any employees or collaborators to, assign all right title and interest
                                         in and to any such Results to Sandoz or its designee, and to execute promptly all documents
                                         and take all such other action as may be reasonably requested by Sandoz in order to permit
                                         Sandoz to obtain the benefit of its rights under this Agreement.

		4.5	In so far as the assignment under clause
                                         4.3 is not possible for legal reasons, the Service Provider/Institution grants Sandoz
                                         the exclusive right, which is unlimited in terms of

    	4 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

duration, territorial scope and
content, as well as being capable of assignment and sub-licensing, to exploit the Results for all known or currently unknown types
of exploitation to the broadest possible extent. This includes, in particular, the right to reproduce, disseminate, publish, exhibit,
lecture on, perform, demonstrate, make available to the public, broadcast, re-broadcast and otherwise reproduce the Results in
any form, in all media, in all services, via all methods of transmission and regardless of the method and apparatus used for the
purpose. This also includes the right to change, translate, work on or otherwise alter the Results and to exploit the results
obtained in these ways in the same ways as listed above.

		4.6	The Service Provider/Institution shall
                                         be solely responsible for any payments due to its employees and collaborators for the
                                         assignment of any inventions or other Results according to the applicable law. Sandoz’
                                         payments for the Services shall be deemed to include consideration for such payments.

		4.7	The Service Provider/Institution shall
                                         grant Sandoz access to all primary data generated in the course of the Services, including
                                         without limitation electronic raw data and data contained in laboratory notebooks. Sandoz
                                         shall have the right to make copies of the Service Provider/Institution’s primary
                                         data at regular intervals in the case of laboratory data.

		4.8	The Service Provider/Institution warrants
                                         that it is entitled to use the materials and technology which it will use to perform
                                         the Services.

		5.	Confidentiality and Non-Use

		5.1	All information, including without
                                         limitation all Work Orders, data, results, reports, Materials and trade secrets, and
                                         all information about compounds which is disclosed to the Service Provider/Institution
                                         by or on behalf of Sandoz or its Affiliates or which is developed or generated by the
                                         Service Provider/Institution or its collaborators in connection with this Agreement or
                                         the Services conducted hereunder (collectively “Confidential Information”),
                                         shall be regarded as confidential. The terms of and the existence of this Agreement shall
                                         also constitute Confidential Information.

		5.2	The Service Provider/Institution shall
                                         not use Confidential Information for any purpose other than the performance of Services
                                         under this Agreement.

		5.3	The Service Provider/Institution shall
                                         not disclose or provide Confidential Information to any third party. Employees and collaborators
                                         of the Service Provider/Institution bound by confidentiality obligations not less strict
                                         than those set out herein, who are under the supervision and control of the Service Provider/Institution,
                                         shall not be regarded as third parties. Disclosure shall be made only to such employees
                                         and collaborators who need to know or to have the Confidential Information for the purpose
                                         of conducting Services under this Agreement.

		5.4	The Service Provider/Institution shall
                                         only copy any documents containing Confidential Information or prepare any extracts from
                                         such documents for the purpose of this Agreement.

    	5 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		5.5	The Service Provider/Institution shall
                                         promptly destroy or provide to Sandoz, as per Sandoz’s request (which may be made
                                         at any time), all documents (including electronic files) containing or relating to Confidential
                                         Information (including all data and results generated in Services, which shall be provided
                                         in electronic form), except for one copy which is to be retained in the confidential
                                         files of the Service Provider/Institution for record purposes only. If requested by Sandoz,
                                         the Service Provider/Institution shall promptly confirm destruction of the documents
                                         to Sandoz in writing. Notwithstanding the aforesaid, Provider/Institution is not obliged
                                         to return or destroy Confidential Information contained in regular IT-Backups, provided
                                         those back-ups are not reopened/recovered to make further use or disclosure.

		5.6	The above obligations shall not apply
                                         to:

		(a)	Confidential Information which
                                         is, at the time of disclosure, in the public domain or thereafter becomes part of the
                                         public domain otherwise than by the act or omission of the Service Provider/Institution
                                         or its employees or agents;

		(b)	Confidential Information that the
                                         Service Provider/Institution can demonstrate by written evidence was in its possession
                                         prior to its disclosure by Sandoz; or

		(c)	Confidential Information which
                                         the Service Provider/Institution received from any third party not engaged in the Services
                                         conducted under this Agreement, where such information is not subject to an obligation
                                         of confidentiality or secrecy in favour of Sandoz or any of its Affiliates.

		5.7	The Service Provider/Institution warrants
                                         that its employees and collaborators who will have access to Confidential Information
                                         will be bound by confidentiality and non-use obligations not less strict than those set
                                         out herein, and that they will comply with those obligations.

		5.8	The Service Provider/Institution may
                                         disclose Confidential Information if requested pursuant to an order of a competent court
                                         or administrative agency, provided that the Service Provider/Institution has informed
                                         Sandoz thereof in writing, and has used reasonable efforts to limit the scope of the
                                         disclosure and to obtain confidential treatment by the court or administrative agency
                                         of Confidential Information disclosed pursuant to such order.

		5.9	The obligations of confidentiality
                                         and non-use in this Section 5 shall survive the expiry or termination of this Agreement
                                         for 15 (fifteen) years.

		6.	This section intentionally blank

		7.	Audits, Inspections and Compliance with
                                         Laws

		7.1	It is agreed that authorised representative(s)
                                         of Sandoz, and/or its Affiliates who are not direct competitors to Service Provider/Institution
                                         may arrange, with twenty (20) days advance notice, at no cost to Sandoz to during regular
                                         business hours examine, audit and

    	6 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

inspect the Service Provider/Institution’s
facilities with respect to the Services, including, but not limited to, the facilities, systems, processes and documentation.

		7.2	The Service Provider/Institution warrants
                                         that it has, and shall continue to have for the duration of this Agreement, all of the
                                         authorisations required under the applicable laws and regulations to perform the in-vitro
                                         experimental work involved in performing the Services at its facilities.

		7.3	The Service Provider/Institution shall
                                         conduct the Services in compliance with all applicable laws, regulations, ordinances,
                                         and guidelines.

		7.4	Service Provider/Institution represents
                                         and warrants that this Agreement and any Work Other thereunder will be performed in material
                                         compliance with all applicable laws and regulations, relating to health, safety, and
                                         environment, fair labour practices and unlawful discrimination.

		7.5	Responsible Procurement. Sandoz promotes
                                         the societal and environmental values of the United Nations Global Compact to its Third
                                         Party Suppliers. Sandoz expect suppliers with whom it works to comply with the law and
                                         to adhere to ethical business practices set out in the Novartis Supplier Code referenced
                                         in Annex 2.

Service Provider/Institution
shall:

		·	Familiarize
                                         themselves with the requirements of the Novartis Supplier Code.

		·	Provide
                                         information on request to Sandoz associates concerning labour, health and safety, environment,
                                         animal welfare, anti-bribery and fair competition, and data protection and privacy practices,
                                         in the form requested.

		·	Allow
                                         Sandoz associates (or Sandoz-nominated third Party experts) adequate access for the purposes
                                         of auditing compliance with these standards.

		·	Mediate
                                         identified non-compliances with the Novartis Supplier Code and report remediation progress
                                         to Novartis on request.

The Novartis Supplier Code,
and other codes, policies and guidelines can be found at: https://www.novartis.com/about-us/corporate-responsibility/resources-news/codes-policies-guidelines

Service Provider/Institution
acknowledges and agrees that the Novartis Supplier Code forms an integral part of this Agreement and understands that failure
to adhere to these standards and/or obstructing/refusing Sandoz’ audit rights as stated in the Novartis Supplier Code shall
constitute a material breach of this Agreement and entitle Sandoz to immediately terminate the Agreement by written notice without
compensation.

    	7 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		8.	Payment Terms

		8.1	In consideration of the satisfactory
                                         performance of the Services, Sandoz will reimburse Service Provider/Institution in accordance
                                         with the Work Order. Service Provider/Institution bears the sole responsibility for compensation
                                         (including overtime to hourly employees, if applicable) of Service Provider/Institution’s
                                         employees. Sandoz shall make payment against every invoice within sixty (60) days of
                                         its receipt of the invoice (also if it is submitted electronically according to 8.9).
                                         Service Provider/Institution shall send the invoice to the address specified on the applicable
                                         Work Order/Purchase Order.

		8.2	Should the Work Order state that Sandoz
                                         will reimburse Service Provider/Institution for out-of-pocket expenses incurred by Service
                                         Provider/Institution in performing the Services, Sandoz shall do so, provided that such
                                         expenses are necessary for the performance of the Services, are reasonable (i.e., not
                                         luxury or first-class) and have been approved in writing, and in advance, by Sandoz.
                                         Each such expense shall be billed to Sandoz promptly after it is incurred but no more
                                         frequent than monthly, at actual cost, i.e., without mark-up or surcharge, and each expense
                                         shall be supported by a receipt or other appropriate documentation.

		8.3	Each invoice for payment shall clearly
                                         state the following

		·	Name
                                         of the requisitioner in the subject line (not in the address) and Purchase Order (PO#)
                                         number

		·	Logo/vendor
                                         name and address

		·	Correct
                                         address

		·	Invoice
                                         number

		·	Invoice
                                         date

		·	Delivery
                                         date

		·	VAT
                                         %

		·	Total
                                         invoice

		·	Payment
                                         terms: 60 days or as defined with the vendor post arrival at Sandoz

		·	Supplier’s
                                         VAT number

Bank account information (incl.
IBAN/SWIFT)

		8.4	If payments are to be made on a time
                                         and materials basis and Service Provider/Institution anticipates that the amounts to
                                         be billed may exceed the amounts set forth in the relevant Purchase Order or Work Order
                                         by ten percent (10%), then Service Provider/Institution

    	8 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

shall immediately notify Sandoz
of this in writing and submit to Sandoz a revised proposal for consideration. If the payment set forth in the relevant Purchase
Order or Work Order is a fixed sum, the amount billed shall not exceed such sum.

		8.5	All costs and rates set forth in the
                                         Work Order shall remain firm for the duration of the Services, unless otherwise agreed
                                         to in writing by Service Provider/Institution and Sandoz.

		8.6	Service Provider/Institution shall
                                         not perform any Services or incur any expenses prior to the execution of a Work Order
                                         or Purchase Order or that exceed the scope of the Purchase Order or Work Order without
                                         the prior written consent of Sandoz. Sandoz shall have no obligation to pay for Services
                                         performed or expenses incurred by Service Provider/Institution before a Work Order or
                                         Purchase Order is executed or for Services or expenses that exceed those set forth in
                                         the Purchase Order or Work Order.

		8.7	Supplier shall submit invoices aligned
                                         with the Sandoz Purchase Order structure. Within 30 days upon Sandoz request (e.g. per
                                         E-mail), Supplier shall establish an electronic supplier account through Sandoz designated
                                         third party cloud network solution through which Supplier will receive Purchase Orders,
                                         submit invoices and any other relevant documents. It is agreed between the Parties that
                                         Sandoz is not obliged to pay any invoice unless the Supplier has submitted the invoice
                                         electronically through the network.

		9.	Taxes and Social Security Contributions

It shall be the Service Provider/Institution’s
responsibility to comply with any obligations and requests in respect of taxes and social security contributions, if applicable,
which relate to fees received under this Agreement.

		10.	Publications and Publicity

		10.1	The Service Provider/Institution shall
                                         not publish the results of any Services, or any information relating to any Services,
                                         without Sandoz’s prior written approval.

		10.2	Neither Party shall issue any press
                                         release or other form of publicity concerning this Agreement without the prior written
                                         consent of the other Party

		10.3	Furthermore, neither Party will use,
                                         or authorise others to use, the name, symbols, or marks of the other Party in any advertising
                                         or publicity material or make any form of representation or statement which would constitute
                                         an express or implied endorsement by the other Party of any commercial product or service
                                         without that other Party’s prior written approval.

		11.	Review/Discussion/Visits

		11.1	The Service Provider/Institution shall
                                         promptly respond to any request by Sandoz from time to time during the performance of
                                         Services that the Service Provider/Institution and its employers and collaborators review
                                         and discuss with representatives of Sandoz the progress of any Services and related matters.

    	9 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		11.2	If the Service Provider/Institution
                                         encounters any unanticipated problem or abnormal result during the conduct of the Services,
                                         the Service Provider/Institution shall report this to Sandoz without delay, and any further
                                         action to be taken shall be decided in consultation with Sandoz.

		11.3	On reasonable prior notice, representatives
                                         of Sandoz may visit the facilities where the Services are being performed.

		12.	Retention of Material relating to Services

The Service Provider/Institution
shall retain all relevant material (including raw data and notes) related to the Services performed under a particular Work Order,
including experiment records and specimens, for 10 (ten) years following completion of the Services. At the end of that period,
the Service Provider/Institution shall request further instructions from Sandoz. The Service Provider/Institution shall not destroy
any relevant material related to any Services without prior written approval from Sandoz. Payment for storage and retention beyond
the 10 (ten) year period shall be negotiated by the Parties in good faith.

		13.	Purchase Order or Work Order

Any Purchase Order or Work Order
under this Agreement shall form a separate and distinct Agreement between the Parties to the Purchase Order or Work Order. In
case of any inconsistency between the terms of this Agreement and any Purchase Order or Work Order, this Agreement shall prevail
unless the Purchase Order or Work Order expressly specifies that it shall prevail over this Agreement. Where an Affiliate has
executed a Purchase Order or Work Order, references to “Sandoz” shall be read as references to the relevant Affiliate.
Sandoz shall not have any obligations in respect of Purchase Orders or Work Orders executed by Affiliates of Sandoz. Work Orders
shall be substantially in the form of Annex 1 to this Agreement and Purchase Order and Work Orders shall specify the details of
the Services to be performed, deliverables (with specifications), timelines, fees and the commercial conditions.

		14.	Assignment

This Agreement shall not be assigned
to any third party without the prior written consent of the other Party, except that Sandoz shall be entitled to assign this Agreement
to any of its Affiliates, or to any third party in connection with the sale or merger of all or a substantial portion of its business,
without the Service Provider/Institution’s consent.

		15.	Subcontracting

		15.1	The Service Provider/Institution shall
                                         not subcontract all or part of any Services without the prior written approval of Sandoz.
                                         Any such approval shall not relieve the Service Provider/Institution of its obligations
                                         under this Agreement.

		15.2	Prior to engaging any subcontractor,
                                         Service Provider/Institution shall inform such subcontractor of all relevant obligations
                                         and restrictions relevant to the performance of

    	10 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

the Services, and enter into
written contracts binding each subcontractor to terms no less strict than those in this Agreement, and shall, upon Sandoz’
request, provide written verification of the technical expertise and qualifications of all subcontractors. Service Provider/Institution
shall be responsible for the selection, retention and compensation of such authorized subcontractors engaged to perform any Services
under this Agreement. All such subcontractors shall be retained directly by Service Provider/Institution and no contractual relationship
or financial obligation shall be created between Sandoz and any subcontractor. Service Provider shall bear the cost of any subcontracting
of Services under this Agreement.

If a Work Order is executed,
Subcontractors used in the performance of the Services described herein are detailed in Schedule C to Annex i.

		16.	Indemnification and Liability

		16.1	The Service Provider/Institution shall
                                         indemnify and hold harmless Sandoz, its Affiliates and their respective officers, directors,
                                         representatives, employees and agents, against all claims, actions, litigations, damages
                                         and liabilities (collectively, “Claims”) against any of the foregoing, to
                                         the extent arising from the negligence, omission, wrongful conduct or wilful misconduct
                                         by the Service Provider/Institution, its collaborators or its subcontractors, in connection
                                         with or relating to this Agreement or a Work Order, or breach of one of the foregoing,
                                         and the Service Provider/Institution agrees to bear all costs and expenses, including
                                         reasonable attorney’s fees, incurred by or on behalf of Sandoz or any other indemnified
                                         person in connection with the defence or settlement of such Claims. Sandoz shall promptly
                                         notify the Service Provider/Institution of any such Claim in writing.

		16.2	Service Provider’s/Institution’s
                                         liability shall be governed by the German statutory provisions.

		16.3	Sandoz’ and its Affiliate’s
                                         liability shall be unlimited (i) in respect of losses caused by acting intentionally
                                         or with gross negligence, (ii) in respect of breaching essential contractual obligations,
                                         namely those obligations which must be complied with in order to make it possible for
                                         the contract to be properly performed at all and which the Service Provider normally
                                         relies on being fulfilled and may so rely (cardinal obligations), (iii) in respect of
                                         defects which have been fraudulently concealed, (iv) in respect of losses arising from
                                         death, bodily injury, or harm to health, (v) in respect of claims under the Law on Product
                                         Liability (Produkthaftungsgesetz), and (vi) in the event that Sandoz expressly assumes
                                         a guarantee as to quality. Any more extensive liability on the part of Sandoz is excluded.

		17.	Notices

		17.1	Except as otherwise expressly provided,
                                         all notices issued in connection with this Agreement (“Notice”) shall be
                                         in writing and sent by registered mail, courier service, or facsimile (provided that
                                         such facsimile shall be confirmed by letter, sent by registered mail or courier service)
                                         to the other Party.

    	11 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		17.2	The Notice shall be deemed to have
                                         been properly served if addressed to:

Sandoz Intentional GmbH

Industriestrasse 25

D-83607 Holzlcirchen

Sandoz International

Attn: Head Legal Global Commercial Operations and D&R

and, if the Notice concerns a
Work Order, to the person specified in the relevant Work Order.

or

Ares Genetics GmbH

Karl-Farkas Gasse 18

1030 Wien

Austria

Attention: Dr. Andreas Posch, Managing Director

or such other address or addresses
of which such Party shall have given written notice not less than 7 (seven) days before the Notice is dispatched.

		17.3	Any such Notice shall be deemed to
                                         be given as follows:

		(a)	If in writing: when delivered by
                                         post or courier service;

		(b)	If by facsimile: when received,
                                         provided it is followed by a letter by mail or courier service within 5 (five) working
                                         days.

		17.4	A Notice given in accordance with
                                         the above but received on a non-working day or after business hours in the place it is
                                         received will only be deemed to be given on the next working day in the place of receipt.

		18.	Entire Agreement, Amendments

		18.1	This Agreement, including any Work
                                         Orders issued hereunder, represents the entire understanding between the Parties with
                                         regard to the Services.

		18.2	No amendment to this Agreement or
                                         any Work Order will be effective or binding unless it is in writing signed by both Parties.

		18.3	Neither this Agreement nor any Work
                                         Order shall be modified except by a written agreement signed by both Parties specifying
                                         that it is a modification to this Agreement or the Work Order, respectively.

		18.4	The failure of a Party to insist upon
                                         strict adherence to any term of this Agreement or a Work Order on any occasion shall
                                         not be considered an amendment or deprive that Party

    	12 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

of the right to insist upon strict
adherence to that term or any other term of this Agreement, the Work Order or any other Work Order.

		19.	Debarment

The Service Provider/Institution
hereby represents and warrants that neither the Service Provider/Institution nor any employee, collaborator or sub-contractor
involved in performing the Services has been debarred under Section 306(a) or (b) of the U.S. Federal Food, Drug and Cosmetic
Act, if applicable. If at any time after execution of this Agreement the Service Provider/Institution becomes aware that it or
any employee, collaborator or sub-contractor involved in the Services is the process of being debarred, the Service Provider/Institution
shall notify Sandoz without delay.

		20.	Independent Contractor

The Service Provider/Institution
shall perform the Services as an independent contractor and, as such, neither the Service Provider/Institution nor its employees
shall be entitled to any benefits applicable to employees of Sandoz. Neither Party is authorised or empowered to act as agent
for the other for any purpose and shall not on behalf of the other enter into any contract, warranty or representation as to any
matter. Neither Party shall be bound by the acts or conduct of the other.

		21.	Severability

If any term or provision of this
Agreement is held to be invalid or unenforceable, in whole or in part, under any applicable enactment or rule of law, such illegality
or unenforceability shall not affect the remainder of this Agreement, and the parties shall in good faith attempt to substitute
a valid and enforceable provision which achieves to the nearest extent possible the same effect as would have been achieved by
the invalid or unenforceable provision.

		22.	Waiver

Any delay or omission on the
part of either Party in the exercise of its rights hereunder will not impair those rights nor will it constitute a renunciation
or waiver of those rights. Any waiver by either party of any term or condition of this Agreement in any one instance shall not
be deemed or construed to be a waiver of such term or condition for any other instance in the future (whether similar or dissimilar)
or of any subsequent breach hereof.

		23.	Conflict of Interest

The Service Provider/Institution
confirms that neither it nor its collaborators have any obligations to any third party, and that no third party has any rights,
that might be in conflict with the obligations under this Agreement, and that neither the Service Provider/Institution nor its
collaborators will enter into any such agreements during the term hereof without the prior written consent of Sandoz.

    	13 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		24.	Jurisdiction

This Agreement is construed in
accordance with, and governed by, the substantive laws of Germany, without regard to the conflicts of law provisions thereof.
Any disputes under or in connection with this Agreement that cannot be settled amicably shall exclusively be submitted to the
competent courts of Munich, Germany, without restricting any rights of appeal.

		25.	Data Protection and Security

		25.1	In the event that the Parties determine
                                         that personal data is required for the performance of Services, the following regulations
                                         apply:

In the course of carrying out
this Agreement and/or Purchase Order(s)/Work Order(s), the Parties shall comply with the applicable data protection laws and regulations
at any given time and shall ensure that persons deployed by them comply with them. In particular, the Service Provider/Institution
shall maintain adequate technical and organizational measures (Article 32 of the GDPR) to ensure a level of security of personal
data appropriate to the risk.

The Service Provider/Institution
shall design its internal organizational structures in such a way that they comply with the applicable data protection laws and
regulations meet the special data protection requirements and that Sandoz’ personal data is to protected from misuse and
loss. The Service Provider/Institution shall require any natural person acting under his authority who has access to personal
data to maintain integrity and confidentiality as per Article 5 (i)(f) GDPR.

If, in the course of performing
its obligations under this Agreement and/or Work Order(s), the Service Provider/Institution comes into contact with Sandoz’
personal data (in particular relating to employees or contractual partners) in accordance with the regulations, then to the extent
that this is necessary according to the applicable data protection law, the Service Provider/Institution shall conclude an agreement
on data processing with Sandoz (Article 28 of the GDPR) based on the Template Processing in accordance with Article 28 General
Data Protection Regulation (GDPR) in Annex 3 attached to this Agreement.

In the course of the execution
of this Agreement and/or Work Order(s), personal data of the Service Provider/Institution may be transferred to Sandoz, Sandoz’
affiliates or Sandoz’ service providers. In particular, Sandoz processes personal data contained in this Agreement and/or
Work Order(s) for contractual execution and documentation purposes. Personal data may thereby be accessed by Sandoz’ affiliates
in Switzerland and/or by IT-service providers providing hosting and support services to Sandoz. Where necessary, Sandoz ensures
an appropriate level of data protection through appropriate contracts. Individuals whose personal data are processed, may claim
their data subject rights as per Chapter 3 of the GDPR towards Sandoz.

Service Provider/Institution
shall not use or disclose any health, medical, employee or other Personal Data, either in written or electronic form, that Service
Provider/Institution

    	14 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

creates, receives, maintains,
or transmits as a result of performing the Services, other than as expressly permitted or required by this Agreement.

		25.2	At any time during the processing
                                         of Personal Data, Service Provider/Institution shall notify Sandoz immediately (but no
                                         later than (3) days from the date) of any data security breach involving Sandoz data.
                                         Service Provider/Institution agrees to assist and cooperate with Sandoz concerning any
                                         disclosures to affected parties, government or regulatory agencies and with any other
                                         remedial measures requested by Sandoz or required under any law. Data Security Breach
                                         shall mean:

		(a)	the loss or misuse (by any means)
                                         of Personal Data;

		(b)	the inadvertent, unauthorised and/or
                                         unlawful processing, access, disclosure, alteration, corruption, transfer, sale or rental,
                                         destruction or use of Personal Data; or

		(c)	any other act or omission that
                                         compromises the security, confidentiality, and/or integrity of Personal Data.

		25.3	Service Provider/Institution shall
                                         take reasonable steps to ensure that each individual whose personal data were, or are,
                                         in its possession is able to assert his or her rights of access to view and correct his
                                         or her Personal Data. Service Provider/Institution shall notify Sandoz promptly, but
                                         no later than five (5) days from its receipt of any communication received from an individual
                                         whose Personal Data were, or are, in its possession relating to said individual’s
                                         rights of access or to correct his or her Personal Data and shall comply with all instructions
                                         of Sandoz in responding to such communications.

    	15 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

IN WITNESS WHEREOF, the Parties intending
to be bound have caused this Agreement to be executed by their duly authorised representatives as of the date of last signature
below.

	SANDOZ INTERNATIONAL GMBH	ARES GENETICS GMBH
	By: /s/ NG Warwick	By: /s/ Andreas Posch
	Name: NG Warwick	Name: Dr. Andreas Posch
	Title: Chief Medical Officer	Title: Managing Director & CEO
	Date: 17 December 2018	Date: 14 December 2018
	 	 
	By: /s/ Kristina Albert	By: /s/ Achim Plum
	Name: Kristina Albert	Name: Dr. Achim Plum
	Title: Head HR Global Product Development Functions	Title: Managing Director
	Date: 17 December 2018	Date: 14 December 2018

 

    	16 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

Annex 1

(SAMPLE)

WORK ORDER AGREEMENT

between

[       ]

(the “Service Provider/Institution”)

and

Sandoz International GmbH 

Industriestrafge 18

83607 Holzkirchen, Germany

(“Sandoz”)

This work order (“Work
Order”) shall be effective as of the Effective Date below. It is subject to the terms of the Services Frame Agreement
(“Agreement”) between Sandoz and Service Provider/Institution dated [].

		1.	CONTRACT RESEARCH-RELATED INFORMATION

	Effective
    Date:	 
	Test
    Compound and Study No.:	 
	Expected
    Services Completion Date	 
	Total
    Contract Value	 
	Services
    Frame

    Agreement expiry date	 

 

		2.	RESPONSIBILITIES OF SERVICE PROVIDER/INSTITUTION

Sandoz and the Service Provider/Institution
agree that the Service Provider/Institution, either exclusively or jointly with Sandoz or its Affiliates or its authorised agent(s),
shall have the responsibilities and shall perform the tasks as specified in the Study Specifications attached hereto as Schedule
B and incorporated herein by reference and other documents which are attached hereto or incorporated by reference.

Subcontracting by the Service
Provider/Institution in the performance of the Services and the performance of the Services by the subcontractors shall be bound
by the terms and conditions of the Agreement. Subcontractors used in the performance of the Services described herein are detailed
in Schedule C.

    	17 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

3.                 
NOTICE

Any notice required or permitted
hereunder shall be in writing and shall be deemed given as of the date if it is (A) delivered by hand or (B) sent by registered
or certified mail, postage prepaid, return receipt request, and addressed to the party to receive such notice at the address set
forth below, or such other address as is subsequently specified in writing, as well as any persons so designated under the Agreement
itself:

If to Sandoz:

	Invoicing
    and Payment Matters:	Billing
    address:

    Salutas Pharma GmbH

    Zentrale

    Kreditorenbuchhaltung

    Otto-von-Guericke-Allee 1

    39179 Barleben

    Germany	 
	Administrative
    / Contractual Matters:	Novartis Business Services
 City Green Court
 Hvezdova 1734/2c
 140 00, Praha 4
 Czech Republic
 FAO Nina Sedlakova

                                                                                [***]
	 
	Technical
    Matters:	Industriestr.
    25

    D-83607 Holzkirchen

    Germany	 

 

If to Service Provider/Institution:

	Technical
    Matters:	 	 
	Contract
    / Payment Matters:	 	 

 

    	18 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

4.                 
MODIFICATIONS AND ADDITIONAL TERMS FOR THIS CONTRACT SERVICES:

[CAUTION: The provisions
of this section supersede any conflicting provisions of the Services Frame Agreement.]

5.                 
LIST OF ATTACHMENTS:

		·	Budget
                                         and Payment Schedule (Schedule A)

		·	Study
                                         Specification Worksheet (Schedule B)

		·	Subcontractors
                                         (Schedule C)

		·	Service
                                         Provider/Institution Proposal and Budget (Schedule D)

		·	Technical
                                         Protocol (Schedule F) [INCLUDE FOR REF LABS]

		·	Quality
                                         and Compliance Questionnaire (Schedule G) [INCLUDE FOR REF LABS]

		·	Press
                                         release (according to Art.17 EU Market Abuse Regulation) (Schedule H)

6.                 
COST AND PAYMENT

Payment shall be made to the
Service Provider/Institution according to Schedule A appended hereto and incorporated herein by reference. All costs outlined
on Schedule A shall remain firm for the duration of the Services, unless otherwise agreed to in writing by the Service Provider/Institution
and Sandoz.

In Witness Whereof, the parties hereto have executed
this Work Order in duplicate by proper persons thereunto duly authorised

 

	SANDOZ INTERNATIONAL,
    GMBH	 	(SERVICE PROVIDER/
    INSTITUTION)
	By: 

        Name: 

        Title: 

        Date: 
	 	By: 

        Name: 

        Title: 

        Date: 

	 	 	 
	By: 

        Name: 

        Title: 

        Date: 
	 	By: 

        Name: 

        Title: 

        Date: 

 

    	19 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

Schedule A

BUDGET AND PAYMENT SCHEDULE

INSERT/ATTACH BUDGET GRID

INSERT/ATTACH PAYMENT SCHEDULE

MINIMUM SPLIT OF REQUIRED INFORMATION
TO BE INCLUDED IN BUDGET GRID:

		·	Service
                                         Provider/Institution Fees and Direct Costs

		·	Pass-Through
                                         Costs and Expenses

		·	Total
                                         Contract Value

 

 

    	20 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule B

STUDY SPECIFICATIONS

 

 

    	21 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule C

Subcontractors

Subcontractors to Service Provider/Institution
in the performance of the Services described herein.

[Please indicate if applicable -
Yes/No. If Yes, complete table in full. If No, please enter N/A across first row of table]

	Services performed 

    by Subcontractor	Subcontractor
    

    Registered Name	Subcontractor
    

    Registered Address	Location
    of Services Performed by 

    Subcontractor
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

Any change to the above information
is considered a change in scope. Service Provider/Institution will prepare a contract amendment to update the information accordingly.

    	22 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule D

Service Provider/Institution Proposal
and Budget

 

 

    	23 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule F

Technical Protocol

 

 

    	24 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule G

Quality and Compliance Questionnaire

 

 

    	25 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Annex 2

NOVARTIS SUPPLIER CODE

https://www.novartis.com/sites/www.novartis.com/files/novartis-supplier-code-en-2017.pdf

 

 

    	26 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Annex 3:

Processing in accordance with Article
z8 General Data Protection

Regulation (GDPR)

[as of: May 2017]

Agreement

between

 

 

		-	the Controller — hereinafter
                                         referred to as the Client -

 

and

 

 

		-	the Processor - hereinafter referred
                                         to as the Supplier

 

[When applicable: Authorised Representative in accordance
with Article 27 GDPR: 

 

 

Please Note

The specific provisions according
to Article 28 Paragraph 3 GDPR should be incorporated into the Agreement in their entirety and be used as a Checklist. The alternatives
applicable for the specific service relationship should be ticked. Empty fields are to be filled in as applicable to the specific
requirements of each individual Order or Contract. Systems of payment and liability conditions concerning the specific services
of the Supplier should be agreed in the main contract.

		1.	Subject matter and duration of the Order or Contract

(1) Subject matter

		□	The Subject matter of the Order
                                         or Contract results from the Service Agreement/SLA/ .......... dated ..........,
                                         which is referred to here (hereinafter referred to as Service

                                         Agreement).

or

 

    	27 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		□	The Subject matter of the Order or
                                         Contract regarding the processing of data is the execution of the following services
                                         or tasks by the Supplier.....................................................

                                         (Definition of the services or tasks)

(2) Duration

		□	The duration of this Order or
                                         Contract corresponds to the duration of the Service Agreement. or (specifically, if no
                                         Service Agreement regarding the Duration exists)

		□	The Order or Contract will be
                                         authorised for one time execution only.

or

□The
Duration of this Contract is limited to

or

		□	The Contract is authorised for
                                         an unlimited period and can be cancelled by either party with a notice period of .......
                                         (time period) to ........ (deadline) . This does not prejudice the right to termination
                                         of the contract without notice.

		2.	Specification of the Order or Contract Details 

(1) Nature and Purpose of the intended
Processing of Data

		□	Nature and Purpose of Processing
                                         of personal data by the Supplier for the Client are precisely defined in the Service
                                         Agreement dated...............

or

		□	Detailed description of the Subject
                                         Matter with regard to the Nature and Purpose of the services provided by the Supplier:
                                         .................

The undertaking of the contractually
agreed Processing of Data shall be carried out exclusively within a Member State of the European Union (EU) or within a Member
State of the European Economic Area (EEA). Each and every Transfer of Data to a State which is not a Member State of either the
EU or the EEA requires the prior agreement of the Client and shall only occur if the specific Conditions of Article 44 et seq.
GDPR have been fulfilled. The adequate level of protection in ............. (e.g. country, territory or specific sectors within
a country)

□has
been decided by the European Commission (Article 45 Paragraph 3 GDPR);

□is
the result of binding corporate rules (Article 46 Paragraph 2 Point bin conjunction with Article 47 GDPR);

		□	is
                                         the result of Standard Data Protection Clauses (Article 46 Paragraph 2 Points c and d
                                         GDPR);

 

    	28 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

		□	is
                                         the result of approved Codes of Conduct (Article 46 Paragraph 2 Point e in conjunction
                                         with Article 40 GDPR);

		□	is
                                         the result of an approved Certification Mechanism. (Article 46 Paragraph 2 Point f conjunction
                                         with Article 42 GDPR)

□is
established by other means.........(Article 46 Paragraph 2 Point a, Paragraph 3 Points a and b GDPR)

(2) Type of Data

□The
type of personal data used is precisely defined in the Service Agreement under

or

		□	The Subject Matter of the processing
                                         of personal data comprises the following data types/categories (List/Description of the
                                         Data Categories)

□Personal Master Data
(Key Personal Data)

□Contact Data

□Key Contract Data (Contractual/Legal
Relationships, Contractual or Product Interest)

□Customer History

□Contract Billing and
Payments Data

□Disclosed Information
(from third parties, e.g. Credit Reference Agencies or from Public Directories...

□Other:... (Please specify)

(3) Categories of Data Subjects

		□	The Categories of Data Subjects
                                         are precisely defined in the Service Agreement under.........

or

		□	The Categories of Data Subjects
                                         comprise:

□Customers

□Potential
Customers

□Subscribers

□Employees

□Suppliers

□Authorised
Agents

 

 

    	29 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

□Contact
Persons

□Other(Please
specify)

 

 

    	30 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

		3.	Technical and Organisational Measures

(i) Before the commencement of
processing, the Supplier shall document the execution of the necessary Technical and Organisational Measures, set out in advance
of the awarding of the Order or Contract, specifically with regard to the detailed execution of the contract, and shall present
these documented measures to the Client for inspection. Upon acceptance by the Client, the documented measures become the foundation
of the contract. Insofar as the inspection/audit by the Client shows the need for amendments, such amendments shall be implemented
by mutual agreement.

(2) The Supplier shall establish
the security in accordance with Article 28 Paragraph 3 Point c, and Article 32 GDPR in particular in conjunction with Article
5 Paragraph 1, and Paragraph 2 GDPR. The measures to be taken are measures of data security and measures that guarantee a protection
level appropriate to the risk concerning confidentiality, integrity, availability and resilience of the systems. The state of
the art, implementation costs, the nature, scope and purposes of processing as well as the probability of occurrence and the severity
of the risk to the rights and freedoms of natural persons within the meaning of Article 32 Paragraph 1 GDPR must be taken into
account. [Details in Appendix 1]

(3) The Technical and Organisational
Measures are subject to technical progress and further development. In this respect, it is permissible for the Supplier to implement
alternative adequate measures. In so doing, the security level of the defined measures must not be reduced. Substantial changes
must be documented.

		4.	Rectification, restriction and erasure of data

(1) The Supplier may not on its
own authority rectify, erase or restrict the processing of data that is being processed on behalf of the Client, but only on documented
instructions from the Client. Insofar as a Data Subject contacts the Supplier directly concerning a rectification, erasure, or
restriction of processing, the Supplier will immediately forward the Data Subject’s request to the Client.

(2) Insofar as it is included
in the scope of services, the erasure policy, ‘right to be forgotten’, rectification, data portability and access
shall be ensured by the Supplier in accordance with documented instructions from the Client without undue delay.

		5.	Quality assurance and other duties of the Supplier

In addition to complying with the
rules set out in this Order or Contract, the Supplier shall comply with the statutory requirements referred to in Articles 28
to 33 GDPR; accordingly, the Supplier ensures, in particular, compliance with the following requirements:

		a)	□ Appointed Data Protection Officer, who performs his/her
                                         duties in compliance with Articles 38 and 39 GDPR.

 

 

    	31 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

□The
Client shall be informed of his/her contact details for the purpose of direct contact. The Client shall be informed immediately
of any change of Data Protection Officer.

□The
Supplier has appointed Mr/Ms [enter: given name, surname, organisational unit, telephone, e-mail] as Data Protection Officer.
The Client shall be informed immediately of any change of Data Protection Officer.

□His/Her
current contact details are always available and easily accessible on the website of the Supplier.

		b)	□The Supplier is not obliged to appoint a Data Protection
                                         Officer. Mr/Ms [enter: given name, surname, organisational unit, telephone, e-mail]
                                         is designated as the Contact Person on behalf of the Supplier.

		c)	□As the Supplier is established outside the EU &
                                         EEA it designates the following Representative within the Union pursuant to Article 27
                                         Paragraph 1 GDPR: Mr/Ms [enter: given name, surname, organisational unit, telephone,
                                         e-mail].

		d)	Confidentiality in accordance with Article 28 Paragraph 3 Sentence
                                         2 Point b, Articles 29 and 32, Paragraph 4 GDPR. The Supplier entrusts only such employees
                                         with the data processing outlined in this contract who have been bound to confidentiality
                                         and have previously been familiarised with the data protection provisions relevant to
                                         their work. The Supplier and any person acting under its authority who has access to
                                         personal data, shall not process that data unless on instructions from the Client, which
                                         includes the powers granted in this contract, unless required to do so by law.

		e)	Implementation of and compliance with all Technical and Organisational
                                         Measures necessary for this Order or Contract in accordance with Article 28 Paragraph
                                         3 Sentence 2 Point c, Article 32 GDPR [details in Appendix 1]

		f)	The Client and the Supplier shall cooperate, on request, with
                                         the supervisory authority in performance of its tasks.

		g)	The Client shall be informed immediately of any inspections
                                         and measures conducted by the supervisory authority, insofar as they relate to this Order
                                         or Contract. This also applies insofar as the Supplier is under investigation or is party
                                         to an investigation by a competent authority in connection with infringements to any
                                         Civil or Criminal Law, or Administrative Rule or Regulation regarding the processing
                                         of personal data in connection with the processing of this Order or Contract.

		h)	h)Insofar as the Client is subject to an inspection by
                                         the supervisory authority, an administrative or summary offence or criminal procedure,
                                         a liability claim by a Data Subject or by a third party or any other claim in connection
                                         with the Order or Contract data processing by the Supplier, the Supplier shall make every
                                         effort to support the Client.

		i)	The Supplier shall periodically monitor the internal processes
                                         and the Technical and Organizational Measures to ensure that processing within his area
                                         of responsibility is in accordance with the requirements of applicable data protection
                                         law and the protection of the rights of the data subject.

		j)	Verifiability of the Technical and Organisational Measures
                                         conducted by the Client as part of the Client’s supervisory powers referred to
                                         in item 7 of this contract.

 

 

    	32 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

		6.	Subcontracting

(1) Subcontracting for the purpose
of this Agreement is to be understood as meaning services which relate directly to the provision of the principal service. This
does not include ancillary services, such as telecommunication services, postal / transport services, maintenance and user support
services or the disposal of data carriers, as well as other measures to ensure the confidentiality, availability, integrity and
resilience of the hardware and software of data processing equipment. The Supplier shall, however, be obliged to make appropriate
and legally binding contractual arrangements and take appropriate inspection measures to ensure the data protection and the data
security of the Client’s data, even in the case of outsourced ancillary services.

(2) The Supplier may commission subcontractors
(additional contract processors) only after prior explicit written or documented consent from the Client.

a) □Subcontracting is not permitted.

b) □The
Client agrees to the commissioning of the following subcontractors on the condition of a contractual agreement in accordance with
Article 28 paragraphs 2-4 GDPR:

 

	Company subcontractor	Address/country	Service
	 	 	 
	 	 	 

c) □Outsourcing
to subcontractors or

□       Changing
the existing subcontractor

are permissible
when:

		-	The Supplier submits such an outsourcing
                                         to a subcontractor to the Client in writing or in text form with appropriate advance
                                         notice; and

		-	The Client has not objected to
                                         the planned outsourcing in writing or in text form by the date of handing over the data
                                         to the Supplier; and

		-	The subcontracting is based on
                                         a contractual agreement in accordance with Article 28 paragraphs 2-4 GDPR.

(3) The transfer of personal data from
the Client to the subcontractor and the subcontractors commencement of the data processing shall only be undertaken after compliance
with all requirements has been achieved.

(4) If the subcontractor provides the
agreed service outside the EU/EEA, the Supplier shall ensure compliance with EU Data Protection Regulations by appropriate measures.
The same applies if service providers are to be used within the meaning of Paragraph 1 Sentence 2.

 

    	33 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

(5) Further outsourcing by the subcontractor

□Is
not permitted;

□Requires
the express consent of the main Client (at the minimum in text form);

□Requires
the express consent of the Supplier (at the minimum in text form);

All contractual provisions in the contract
chain shall be communicated to and agreed with each and every additional subcontractor.

		7.	Supervisory powers of the Client

(1) The;Client has the right, after consultation
with the Supplier, to carry out inspections or to have them carried out by an auditor to be designated in each individual case.
It has the right to convince itself of the compliance with this agreement by the Supplier in his business operations by means
of random checks, which are ordinarily to be announced in good time.

(2) The Supplier shall ensure that the Client
is able to verify compliance with the obligations of the Supplier in accordance with Article 28 GDPR. The Supplier undertakes
to give the Client the necessary information on request and, in particular, to demonstrate the execution of the Technical and
Organizational Measures.

(3) Evidence of such measures, which
concern not only the specific Order or Contract, may be provided by

		□	Compliance with approved Codes
                                         of Conduct pursuant to Article 40 GDPR;

		□	Certification
                                         according to an approved certification procedure in accordance with Article 42 GDPR;

		□	Current
                                         auditor’s certificates, reports or excerpts from reports provided by independent
                                         bodies (e.g. auditor, Data Protection Officer, IT security department, data privacy auditor,
                                         quality auditor)

		□	A suitable
                                         certification by IT security or data protection auditing (e.g. according to BSI-Grundschutz
                                         (IT Baseline Protection certification developed by the German Federal Office for
                                         Security in Information Technology (BSI)) or ISO/IEC 27001).

(4) The Supplier may claim remuneration for enabling
Client inspections.

		8.	Communication in the case of infringements by the Supplier

(1) The Supplier shall assist the Client
in complying with the obligations concerning the security of personal data, reporting requirements for data breaches, data protection
impact assessments and prior consultations, referred to in Articles 32 to 36 of the GDPR. These include:

		a)	Ensuring an appropriate level of protection
                                         through Technical and Organizational Measures that take into account the circumstances
                                         and purposes of the processing as well as the projected probability and severity of a
                                         possible infringement of the law as a result

 

    	34 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

of security vulnerabilities and
that enable an immediate detection of relevant infringement events.

b)       The
obligation to report a personal data breach immediately to the Client

		c)	The duty to assist the Client with regard
                                         to the Client’s obligation to provide information to the Data Subject concerned
                                         and to immediately provide the Client with all relevant information in this regard.

d)       Supporting
the Client with its data protection impact assessment

e)       Supporting
the Client with regard to prior consultation of the supervisory authority

(2) The Supplier may claim compensation
for support services which are not included in the description of the services and which are not attributable to failures on the
part of the Supplier.

		9.	Authority of the Client to issue instructions

(1) The Client shall immediately confirm oral
instructions (at the minimum in text form).

(2) The Supplier shall inform the Client
immediately if he considers that an instruction violates Data Protection Regulations. The Supplier shall then be entitled to suspend
the execution of the relevant instructions until the Client confirms or changes them.

		10.	Deletion and return of personal data

(1) Copies or duplicates of the data
shall never be created without the knowledge of the Client, with the exception of back-up copies as far as they are necessary
to ensure orderly data processing, as well as data required to meet regulatory requirements to retain data.

(2) After conclusion of the contracted
work, or earlier upon request by the Client, at the latest upon termination of the Service Agreement, the Supplier shall hand
over to the Client or-subject to prior consent - destroy all documents, processing and utilization results, and data sets related
to the contract that have come into its possession, in a data-protection compliant manner. The same applies to any and all connected
test, waste, redundant and discarded material. The log of the destruction or deletion shall be provided on request.

(3) Documentation which is used to
demonstrate orderly data processing in accordance with the Order or Contract shall be stored beyond the contract duration by the
Supplier in accordance with the respective retention periods. It may hand such documentation over to the Client at the end of
the contract duration to relieve the Supplier of this contractual obligation.

	Place, Date	Place,
    Date
	 	 
	Client

        (Name, Position)

        (Signature)
	Supplier

        (Name, Position)

        (Signature)

 

    	35 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

	Client

        (Name, Position)

        (Signature)
	Supplier

        (Name, Position)

        (Signature)

 

Appendix - Technical and Organisational
Measures

		1.	Confidentiality (Article 32 Paragraph 1 Point b GDPR)

		·	Physical
                                         Access Control

		·	No
                                         unauthorised access to Data Processing Facilities, e.g.: magnetic or chip cards, keys,
                                         electronic door openers, facility security services and/or entrance security staff, alarm
                                         systems, video/CCTV Systems

		·	Electronic
                                         Access Control

                                         No unauthorised use of the Data Processing and Data Storage Systems, e.g.: (secure) passwords,
                                         automatic blocking/locking mechanisms, two-factor authentication, encryption of data
                                         carriers/storage media

		·	Internal
                                         Access Control (permissions for user rights of access to and amendment of data) No unauthorised
                                         Reading, Copying, Changes or Deletions of Data within the system, e.g. rights authorisation
                                         concept, need-based rights of access, logging of system access events

		·	Isolation
                                         Control

                                         The isolated Processing of Data, which is collected for differing purposes, e.g. multiple
                                         Client support, sandboxing;

		·	Pseudonymisation
                                         (Article 32 Paragraph 1 Point a GDPR; Article 25 Paragraph 1 GDPR) The processing of
                                         personal data in such a method/way, that the data cannot be associated with a specific
                                         Data Subject without the assistance of additional Information, provided that this additional
                                         information is stored separately, and is subject to appropriate technical and organisational
                                         measures.

		2.	Integrity (Article 32 Paragraph 1 Point b GDPR)

		·	Data
                                         Transfer Control

                                         No unauthorised Reading, Copying, Changes or Deletions of Data with electronic transfer
                                         or transport, e.g.: Encryption, Virtual Private Networks (VPN), electronic signature;

		·	Data
                                         Entry Control

                                         Verification, whether and by whom personal data is entered into a Data Processing System,
                                         is changed or deleted, e.g.: Logging, Document Management

		3.	Availability and Resilience (Article 32 Paragraph 1 Point
                                         b GDPR)

		·	Availability
                                         Control

                                         Prevention of accidental or wilful destruction or loss, e.g.: Backup Strategy

 

    	36 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

(online/offline; on-site/off-site),
Uninterruptible Power Supply (UPS), virus protection, firewall, reporting procedures and contingency planning

		·	Rapid
                                         Recovery (Article 32 Paragraph 1 Point c GDPR) (Article 32 Paragraph 1 Point c GDPR);

		4.	Procedures for regular testing, assessment and evaluation
                                         (Article 32 Paragraph 1 Point d GDPR; Article 25 Paragraph 1 GDPR)

		·	Data
                                         Protection Management;

		·	Incident
                                         Response Management;

		·	Data
                                         Protection by Design and Default (Article 25 Paragraph 2 GDPR);

		·	Order
                                         or Contract Control

                                         No third party data processing as per Article 28 GDPR without corresponding instructions
                                         from the Client, e.g.: clear and unambiguous contractual arrangements, formalised Order
                                         Management, strict controls on the selection of the Service Provider, duty of pre-evaluation,
                                         supervisory follow-up checks.

 

    	37 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Schedule H

Press Release

 

 

    	38 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
 
 

    

 

Annex 4:

Background-IP of Service Provider/Institution

Tbd., after signing of contract, but
before start of project.

 

    	39 

    	Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]